


=>

Uploading C:\Program Files\Stnexp\Queries\10522958-updated.str



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12 12-13 13-14

exact/norm bonds :

5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12 12-13 13-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5

isolated ring systems :

containing 1 : 10 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS

L1 STRUCTURE UPLOADED

=> d his

(FILE 'HOME' ENTERED AT 21:59:26 ON 23 JAN 2008)

FILE 'REGISTRY' ENTERED AT 21:59:39 ON 23 JAN 2008

L1 STRUCTURE UPLOADED

L2 958 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 22:00:11 ON 23 JAN 2008

L3 37 S L2


L4 2 S US200!-522958/APPS

L5 1 S L3 AND L4

L6 36 S L3 NOT L4

FILE 'REGISTRY' ENTERED AT 22:00:46 ON 23 JAN 2008

>>  
Uploading C:\Program Files\Stnexp\Queries\10522958-updated.scr



ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12 13 14  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12 12-13 13-14  
exact/norm bonds :  
5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12 12-13 13-14  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5  
isolated ring systems :  
containing 1 : 10 :

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS

L1 STRUCTURE UPLOADED

>> d his

(FILE 'HOME' ENTERED AT 21:59:26 ON 23 JAN 2008)

FILE 'REGISTRY' ENTERED AT 21:59:39 ON 23 JAN 2008

L1 STRUCTURE UPLOADED  
L2 958 S L1 958 FULL

FILE 'CAPLUS' ENTERED AT 22:00:11 ON 23 JAN 2008


L3 37 S L2  
L4 2 S US2001-522958/APPS  
L5 1 S L3 AND L4  
L6 36 S L3 NOT L4

FILE 'REGISTRY' ENTERED AT 22:00:46 ON 23 JAN 2008

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS ON STN  
AN 2004:143141 CAPLUS [Full-text](#)

DN 140:199325  
TI Preparation of benzimidazolyl substituted thiophenes as Polo like kinases  
(PLK) inhibitors for treating cancer  
IN Andrews, Clarence W., III; Cheung, Mui; Davis-Ward, Ronda G.; Drewry,  
David Harold; Emmette, Kyle Allen; Hubbard, Robert Dale; Kuntz, Kevin W.;  
Linn, James Andrew; Mook, Robert Anthony; Smith, Gary Keith; Veal, James  
Marvin  
PA Smithkline Beecham Corporation, USA  
SO PCT Int. Appl., 235 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014899	A1	20040219	WO 2003-024272	20030804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SR, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493908	A1	20040219	CA 2003-2493908	20030804
AU 2003265348	A1	20040225	AU 2003-265348	20030804
AU 2003265348	B2	20070816		
EP 1546137	A1	20050629	EP 2003-784888	20030804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013160	A	20050712	BR 2003-13160	20030804
CN 1688576	A	20051026	CN 2003-823755	20030804
JP 20060505522	T	20060216	JP 2004-527723	20030804
NZ 538134	A	20060331	NZ 2003-538134	20030804
RU 2296758	C2	20070410	RU 2005-102390	20030804
ZA 2005000864	A	20060426	ZA 2005-864	20050128
NO 2005000525	A	20050506	NO 2005-525	20050131
US 2006074119	A1	20060406	US 2005-522958	20050131
MX 2005PA01544	A	20050419	MX 2005-PA1544	20050209
IN 2005KN00321	A	20060106	IN 2005-KN321	20050302
PRAI US 2002-402008P	P	20020808		
WO 2003-024272	W	20030804		
OS MARPAT 140:199325				
GI				



AB The title compds. [I, R1 = H, alkyl, COR7, CO2R7, etc.; Q1 = OCH2Ph, NHCH2Ph (both substituted on Ph ring), etc.; n = 0-4; Q2 = OMe, Cl, Br, etc.; R5 = H, halo, alkyl, etc.; R7 = H, alkyl, cycloalkyl, etc.], useful for treating a condition mediated by PLK, were prepared. E.g., a multi-step synthesis of II which showed pIC50 of > 7 in assay for inhibition of PLK1, was given. The pharmaceutical composition comprising the title compds. I is claimed.  
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

>> d 16 tot bib abs hitstr

X L6 ANSWER 1 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN

AN 2007:1420678 CAPLUS [Full-text](#)

DN 148:55071

TI Preparation of benzimidazolylthiophene benzyl ether compounds as PLK1

inhibitors

IN Kuntz, Kevin Wayne; Emerson, Holly Kathleen; Cheung, Mui; Badiang,

Jennifer Gabriel

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 113pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO. (no US appl)	DATE
WO 2007143506	A2	20071213	WO 2007-US70108	20070531
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RB, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2006-810315P	P	20060602 (not art)		
GI				



AB Title compds. represented by the formula I [wherein R1, R2 = independently H, halo, (halo)alkyl, etc.; R3 = H or alkyl; n = 0-2; R4 = independently halo; Y1 = O, (un)substituted amino, -CONH- or -NHCO-; R5 = alkylene; n = 1 or 2; R6 = independently OR7 or NR7R8; R7, R8 = independently H, (cyclo)alkyl, (cyclo)alkenyl or alkynyl; and pharmaceutically acceptable salts or solvates thereof] were prepared as polo-like kinase (PLK) 1 inhibitors for treatment of susceptible neoplasms. For example, II\*HCO2H was provided in a multi-step synthesis starting from 2-chloro-3-nitrobenzaldehyde. I were tested for inhibition of PLK1 and cell proliferation by PLK1 inhibitors.


IT 352909-91-2P, 5-[5,6-Bis(methoxy)-1H-benzimidazol-1-yl]-3-[[[(1R)-1-[2-chloro-5-[[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]ethyl]oxy]-2-thiophenecarboxamide]formate 959909-95-5P, 5-[5,6-Bis(methoxy)-1H-benzimidazol-1-yl]-3-[[[(1R)-1-[2-chloro-3-[[[2-hydroxyethyl]amino]phenyl]ethyl]oxy]-2-thiophenecarboxamide]959910-92-2P, 3-[[[(1R)-1-[3-[[[2-(2-aminoethyl)oxy]-2-chlorophenyl]ethyl]oxy]-5-[5,6-bis(methoxy)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide]959910-91-1P, 3-[[[(1R)-1-[3-[[[2-Aminoethyl]oxy]-2-chlorophenyl]ethyl]oxy]-5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamide]959910-92-2P, 3-[[[(1R)-1-[2-Chloro-3-[[[3-hydroxypropyl]oxy]phenyl]ethyl]oxy]-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl)-2-thiophenecarboxamide]959910-93-3P, 3-[[[(1R)-1-[2-chloro-3-[[[2-hydroxyethyl]oxy]phenyl]ethyl]oxy]-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl)-2-thiophenecarboxamide]959910-94-4P, 3-[[[(1R)-1-[3-[[[2-Aminoethyl]oxy]-2-chlorophenyl]ethyl]oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide]959910-05-5P, 3-[[[(1R)-1-[2-Chloro-3-[[[2-(dimethylamino)ethyl]oxy]phenyl]ethyl]oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl)-2-thiophenecarboxamide]959910-06-6P, 3-[[[(1R)-1-[2-Chloro-3-[[[3-(dimethylamino)propyl]oxy]phenyl]ethyl]oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide]959909-91-2 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 959909-90-1

CMF C27 H30 Cl NS OS S

Absolute stereochemistry.



CM 2

CRN 64-10-6


CMF C H2 O2

O=C-N-OH

RN 959909-95-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(2-hydroxyethyl)amino]phenyl]ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-99-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959910-01-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959910-02-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(3-hydroxypropoxy)phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959910-03-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(2-hydroxyethoxy)phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959910-04-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




● KC1

RN 959910-05-5 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(2-(dimethylamino)ethoxy)phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959910-06-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(3-(dimethylamino)propoxy)phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 115567-85-2, Methyl 5-(1H-benzimidazol-1-yl)-3-hydroxy-2-thiophenecarboxylate 660870-09-7, Methyl 5-[5,6-bis(methoxy)-1H-benzimidazol-1-yl]-3-hydroxy-2-thiophenecarboxylate

RL: RCT (Reactant), RACT (Reactant or reagent)

(preparation of 5-benzimidazolylthiophene-2-carboxamides as PLK1 inhibitors for treatment of neoplasms)


RN 113387-85-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)




RN 660870-09-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)




IT 529276-06-4P, Methyl 5-(5-bromo-1H-benzimidazol-1-yl)-3-hydroxy-2-thiophenecarboxylate 250950-16-5P, Methyl 5-(6-bromo-1H-benzimidazol-1-yl)-3-[(tert-butylidimethylsilyl)oxy]thiophene-2-carboxylate 529276-47-1P, Methyl 5-(5-bromo-1H-benzimidazol-1-yl)-3-[(phenylmethyl)oxy]-2-thiophenecarboxylate 529290-94-2P, Methyl 5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-[(phenylmethyl)oxy]-2-thiophenecarboxylate 529290-95-4P, Methyl 3-hydroxy-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxylate 529290-96-0P 559909-77-4P, Methyl 5-(5-bromo-1H-benzimidazol-1-yl)-3-[(tert-butylidimethylsilyl)oxy]thiophene-2-carboxylate 559909-82-1P 559909-83-2P 559909-84-3P 559909-85-4P 559909-86-5P 559909-87-6P 559909-92-3P, Methyl 5-[5,6-bis(methyloxy)-1H-benzimidazol-1-yl]-3-[[1-(2-chloro-5-iodophenyl)ethyl]oxy]-2-thiophenecarboxylate 559909-93-4P, 5-[5,6-Bis(methyloxy)-1H-benzimidazol-1-yl]-3-[[[R]-1-(2-chloro-5-iodophenyl)ethyl]oxy]-2-thiophenecarboxamide 559909-94-5P, 5-[5,6-Bis(methyloxy)-1H-benzimidazol-1-yl]-3-[[[1R]-1-[2-chloro-5-[[2,5-dioxo-1-pyrrolidinyl]oxy]carbonyl]phenyl]ethyl]oxy]-2-thiophenecarboxamide 559909-96-7P 559909-97-8P, 5-[5,6-Bis(methyloxy)-1H-benzimidazol-1-yl]-3-[[[1R]-1-(2-chloro-3-nitrophenyl)ethyl]oxy]-2-thiophenecarboxamide 559909-98-5P, 3-[[[1R]-1-(3-Amino-2-chlorophenyl)ethyl]oxy]-5-[5,6-bis(methyloxy)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide 559910-00-0P 559910-07-7P, 5-[5,6-Bis(methyloxy)-1H-benzimidazol-1-yl]-3-[[1-(2-chloro-5-iodophenyl)ethyl]oxy]-2-thiophenecarboxamide  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of 5-benzimidazolylthiophene-2-carboxamides as PLK1 inhibitors for treatment of neoplasms)

RN 669870-06-4 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)




RN 929095-46-5 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-(6-bromo-1H-benzimidazol-1-yl)-3-[[1,1-


dimethylethyl)dimethylsilyl]oxy]-, methyl ester (CA INDEX NAME)




RN 929276-47-1 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 929280-84-2 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 929280-85-4 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 929280-90-0 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 3-[[1R]-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

INDEX NAME)

Absolute stereochemistry.




RN 959909-77-4 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-[[[1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester (CA INDEX NAME)



RN 959909-82-1 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 3-[[[1R]-1-[2-chloro-3-[[[1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-83-2 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-[[[1R]-1-[2-


chloro-3-[[[1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959909-84-3 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 3-[[[1R]-1-[2-chloro-3-hydroxyphenyl]ethoxy]-5-[5,6-dimethoxy-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 959909-85-4 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 3-[[[1R]-1-[2-chloro-3-[[[1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]ethoxy]-5-[5,6-dimethoxy-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 959909-86-5 CAPLUS




10522958-updated

13 of 356

CN 2-Thiophenecarboxylic acid, 5-[(1H-benzimidazol-1-yl)-3-[(1R)-1-[(3-(2-bromoethoxy)-2-chlorophenyl)ethoxy]-], methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-87-6 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[(1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-], methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 959909-92-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[1-(2-chloro-5-iodophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)



RN 959909-93-4 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chloro-5-iodophenyl)ethoxy]-5-(5,6-

10522958-updated

15 of 356

dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-98-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(3-amino-2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959910-00-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[(3-(2-bromoethoxy)-2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-], methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 959910-07-7 CAPLUS


CN 2-Thiophenecarboxamide, 3-[1-(2-chloro-5-iodophenyl)ethoxy]-5-(5,6-

10522958-updated

14 of 356

dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-94-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959909-96-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-nitrophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959909-97-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chloro-3-nitrophenyl)ethoxy]-5-(5,6-

10522958-updated

16 of 356

dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)



X L6 ANSWER 2 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1420591 CAPLUS Full-text

DN 148:55070

TI Benzimidazole thiophene compounds and their preparation, pharmaceutical

compositions and use in the treatment of diseases

IN Kuntz, Kevin; Emmette, Kyle Allen; Rheault, Tara Renae; Smith, Stephen;

Hornberger, Keith; Dickson, Hamilton; Cheung, Mui

PA SmithKline Beecham Corporation, USA

SO PCT Int. Appl., 303pp.

CODEN: PIXXD2

DT Patent

LA English

FAN: CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO. (no US case)	DATE
PI WO 2007:143456	A2	20071213	WO 2007-US69879	20070529
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TW				
PRAI US 2006-810526P	P	20060602	(not prior art)	

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention provides benzimidazolylthiophene compds. of formula I, pharmaceutical compns. containing the same, processes for preparing the same and their use as pharmaceutical agents. Compds. of formula I wherein R1 and R2 are independently H, halo, (halo)alkyl, OH and derivs., CN, CONH2 and

deriva., etc., R3 and each R4 are independently H, and (halo)alkyl; Z1, Z2 and Z3 are independently C, CH, and N, provided that at least one of Z1, Z2 and Z3 is C or CH; d is 0, 1 and 2; Y1 is O and NH and deriva.; a is 0 and 1; each R5 is independently C1-3 alkylene; A is 5- to 6-membered heterocyclic ring; b is 0, 1 and 2; each R6 is halo, (haloalkyl)alkenyl, CN, R5-CN, CO2H and deriva., CONH2 and deriva., etc.; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their PLK1 and HCT116 inhibitory activity. From the assay it was determined that compound II exhibited IC50 values of < 0.5  $\mu$ M.

IT 959998-35-7P 959998-78-8P 959998-80-2P

959998-46-8P 959998-89-1P 959998-93-7P

959998-95-7P 959998-99-3P 959998-04-3P

959998-07-6P 959998-27-2P 959998-35-4P

959998-41-8P 959998-42-0P 959998-43-2P


959998-19-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug candidate and intermediate; preparation of benzimidazolylthiophene compds. useful in treatment of diseases)

RN 959998-35-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959998-78-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959998-80-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

CMF C30 H31 C1 N6 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 959998-93-7 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



PAGE 1-A


Absolute stereochemistry.



RN 959998-86-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



PAGE 1-A



RN 959998-89-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 959998-88-0


PAGE 1-B



RN 959998-95-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959998-99-3 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959999-04-3 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959999-07-6 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-37-2 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED




RN 959999-39-4 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED




RN 959999-49-6 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




IT 959999-49-6  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of benzimidazolylthiophene compds. useful in treatment of diseases)


RN 959999-35-0 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED




IT 959999-35-0



RN 959999-41-8 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED



RN 959999-43-0 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED




RN 959999-45-2 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-[[3-(4-piperidinyloxy)phenyl]methoxy]- (CA INDEX NAME)

959999-45-2 959999-46-3 959999-47-4 959999-48-5 959999-49-6 959999-50-7 959999-51-8 959999-52-9 959999-53-10 959999-54-11 959999-55-12 959999-56-13 959999-57-14 959999-58-15 959999-59-16 959999-60-17 959999-61-18 959999-62-19 959999-63-20 959999-64-21 959999-65-22 959999-66-23 959999-67-24 959999-68-25 959999-69-26 959999-70-27 959999-71-28 959999-72-29 959999-73-30 959999-74-31 959999-75-32 959999-76-33 959999-77-34 959999-78-35 959999-79-36 959999-80-37 959999-81-38 959999-82-39 959999-83-40 959999-84-41 959999-85-42 959999-86-43 959999-87-44 959999-88-45 959999-89-46 959999-90-47 959999-91-48 959999-92-49 959999-93-50 959999-94-51 959999-95-52 959999-96-53 959999-97-54 959999-98-55 959999-99-56 959999-100-57 959999-101-58 959999-102-59 959999-103-60 959999-104-61 959999-105-62 959999-106-63 959999-107-64 959999-108-65 959999-109-66 959999-110-67 959999-111-68 959999-112-69 959999-113-70 959999-114-71 959999-115-72 959999-116-73 959999-117-74 959999-118-75 959999-119-76 959999-120-77 959999-121-78 959999-122-79 959999-123-80 959999-124-81 959999-125-82 959999-126-83 959999-127-84 959999-128-85 959999-129-86 959999-130-87 959999-131-88 959999-132-89 959999-133-90 959999-134-91 959999-135-92 959999-136-93 959999-137-94 959999-138-95 959999-139-96 959999-140-97 959999-141-98 959999-142-99 959999-143-100 959999-144-101 959999-145-102 959999-146-103 959999-147-104 959999-148-105 959999-149-106 959999-150-107 959999-151-108 959999-152-109 959999-153-110 959999-154-111 959999-155-112 959999-156-113 959999-157-114 959999-158-115 959999-159-116 959999-160-117 959999-161-118 959999-162-119 959999-163-120 959999-164-121 959999-165-122 959999-166-123 959999-167-124 959999-168-125 959999-169-126 959999-170-127 959999-171-128 959999-172-129 959999-173-130 959999-174-131 959999-175-132 959999-176-133 959999-177-134 959999-178-135 959999-179-136 959999-180-137 959999-181-138 959999-182-139 959999-183-140 959999-184-141 959999-185-142 959999-186-143 959999-187-144 959999-188-145 959999-189-146 959999-190-147 959999-191-148 959999-192-149 959999-193-150 959999-194-151 959999-195-152 959999-196-153 959999-197-154 959999-198-155 959999-199-156 959999-200-157 959999-201-158 959999-202-159 959999-203-160 959999-204-161 959999-205-162 959999-206-163 959999-207-164 959999-208-165 959999-209-166 959999-210-167 959999-211-168 959999-212-169 959999-213-170 959999-214-171 959999-215-172 959999-216-173 959999-217-174 959999-218-175 959999-219-176 959999-220-177 959999-221-178 959999-222-179 959999-223-180 959999-224-181 959999-225-182 959999-226-183 959999-227-184 959999-228-185 959999-229-186 959999-230-187 959999-231-188 959999-232-189 959999-233-190 959999-234-191 959999-235-192 959999-236-193 959999-237-194 959999-238-195 959999-239-196 959999-240-197 959999-241-198 959999-242-199 959999-243-200 959999-244-201 959999-245-202 959999-246-203 959999-247-204 959999-248-205 959999-249-206 959999-250-207 959999-251-208 959999-252-209 959999-253-210 959999-254-211 959999-255-212 959999-256-213 959999-257-214 959999-258-215 959999-259-216 959999-260-217 959999-261-218 959999-262-219 959999-263-220 959999-264-221 959999-265-222 959999-266-223 959999-267-224 959999-268-225 959999-269-226 959999-270-227 959999-271-228 959999-272-229 959999-273-230 959999-274-231 959999-275-232 959999-276-233 959999-277-234 959999-278-235 959999-279-236 959999-280-237 959999-281-238 959999-282-239 959999-283-240 959999-284-241 959999-285-242 959999-286-243 959999-287-244 959999-288-245 959999-289-246 959999-290-247 959999-291-248 959999-292-249 959999-293-250 959999-294-251 959999-295-252 959999-296-253 959999-297-254 959999-298-255 959999-299-256 959999-300-257 959999-301-258 959999-302-259 959999-303-260 959999-304-261 959999-305-262 959999-306-263 959999-307-264 959999-308-265 959999-309-266 959999-310-267 959999-311-268 959999-312-269 959999-313-270 959999-314-271 959999-315-272 959999-316-273 959999-317-274 959999-318-275 959999-319-276 959999-320-277 959999-321-278 959999-322-279 959999-323-280 959999-324-281 959999-325-282 959999-326-283 959999-327-284 959999-328-285 959999-329-286 959999-330-287 959999-331-288 959999-332-289 959999-333-290 959999-334-291 959999-335-292 959999-336-293 959999-337-294 959999-338-295 959999-339-296 959999-340-297 959999-341-298 959999-342-299 959999-343-300 959999-344-301 959999-345-302 959999-346-303 959999-347-304 959999-348-305 959999-349-306 959999-350-307 959999-351-308 959999-352-309 959999-353-310 959999-354-311 959999-355-312 959999-356-313 959999-357-314 959999-358-315 959999-359-316 959999-360-317 959999-361-318 959999-362-319 959999-363-320 959999-364-321 959999-365-322 959999-366-323 959999-367-324 959999-368-325 959999-369-326 959999-370-327 959999-371-328 959999-372-329 959999-373-330 959999-374-331 959999-375-332 959999-376-333 959999-377-334 959999-378-335 959999-379-336 959999-380-337 959999-381-338 959999-382-339 959999-383-340 959999-384-341 959999-385-342 959999-386-343 959999-387-344 959999-388-345 959999-389-346 959999-390-347 959999-391-348 959999-392-349 959999-393-350 959999-394-351 959999-395-352 959999-396-353 959999-397-354 959999-398-355 959999-399-356 959999-400-357 959999-401-358 959999-402-359 959999-403-360 959999-404-361 959999-405-362 959999-406-363 959999-407-364 959999-408-365 959999-409-366 959999-410-367 959999-411-368 959999-412-369 959999-413-370 959999-414-371 959999-415-372 959999-416-373 959999-417-374 959999-418-375 959999-419-376 959999-420-377 959999-421-378 959999-422-379 959999-423-380 959999-424-381 959999-425-382 959999-426-383 959999-427-384 959999-428-385 959999-429-386 959999-430-387 959999-431-388 959999-432-389 959999-433-390 959999-434-391 959999-435-392 959999-436-393 959999-437-394 959999-438-395 959999-439-396 959999-440-397 959999-441-398 959999-442-399 959999-443-400 959999-444-401 959999-445-402 959999-446-403 959999-447-404 959999-448-405 959999-449-406 959999-450-407 959999-451-408 959999-452-409 959999-453-410 959999-454-411 959999-455-412 959999-456-413 959999-457-414 959999-458-415 959999-459-416 959999-460-417 959999-461-418 959999-462-419 959999-463-420 959999-464-421 959999-465-422 959999-466-423 959999-467-424 959999-468-425 959999-469-426 959999-470-427 959999-471-428 959999-472-429 959999-473-430 959999-474-431 959999-475-432 959999-476-433 959999-477-434 959999-478-435 959999-479-436 959999-480-437 959999-481-438 959999-482-439 959999-483-440 959999-484-441 959999-485-442 959999-486-443 959999-487-444 959999-488-445 959999-489-446 959999-490-447 959999-491-448 959999-492-449 959999-493-450 959999-494-451 959999-495-452 959999-496-453 959999-497-454 959999-498-455 959999-499-456 959999-500-457 959999-501-458 959999-502-459 959999-503-460 959999-504-461 959999-505-462 959999-506-463 959999-507-464 959999-508-465 959999-509-466 959999-510-467 959999-511-468 959999-512-469 959999-513-470 959999-514-471 959999-515-472 959999-516-473 959999-517-474 959999-518-475 959999-519-476 959999-520-477 959999-521-478 959999-522-479 959999-523-480 959999-524-481 959999-525-482 959999-526-483 959999-527-484 959999-528-485 959999-529-486 959999-530-487 959999-531-488 959999-532-489 959999-533-490 959999-534-491 959999-535-492 959999-536-493 959999-537-494 959999-538-495 959999-539-496 959999-540-497 959999-541-498 959999-542-499 959999-543-500 959999-544-501 959999-545-502 959999-546-503 959999-547-504 959999-548-505 959999-549-506 959999-550-507 959999-551-508 959999-552-509 959999-553-510 959999-554-511 959999-555-512 959999-556-513 959999-557-514 959999-558-515 959999-559-516 959999-560-517 959999-561-518 959999-562-519 959999-563-520 959999-564-521 959999-565-522 959999-566-523 959999-567-524 959999-568-525 959999-569-526 959999-570-527 959999-571-528 959999-572-529 959999-573-530 959999-574-531 959999-575-532 959999-576-533 959999-577-534 959999-578-535 959999-579-536 959999-580-537 959999-581-538 959999-582-539 959999-583-540 959999-584-541 959999-585-542 959999-586-543 959999-587-544 959999-588-545 959999-589-546 959999-590-547 959999-591-548 959999-592-549 959999-593-550 959999-594-551 959999-595-552 959999-596-553 959999-597-554 959999-598-555 959999-599-556 959999-600-557 959999-601-558 959999-602-559 959999-603-560 959999-604-561 959999-605-562 959999-606-563 959999-607-564 959999-608-565 959999-609-566 959999-610-567 959999-611-568 959999-612-569 959999-613-570 959999-614-571 959999-615-572 959999-616-573 959999-617-574 959999-618-575 959999-619-576 959999-620-577 959999-621-578 959999-622-579 959999-623-580 959999-624-581 959999-625-582 959999-626-583 959999-627-584 959999-628-585 959999-629-586 959999-630-587 959999-631-588 959999-632-589 959999-633-590 959999-634-591 959999-635-592 959999-636-593 959999-637-594 959999-638-595 959999-639-596 959999-640-597 959999-641-598 959999-642-599 959999-643-600 959999-644-601 959999-645-602 959999-646-603 959999-647-604 959999-648-605 959999-649-606 959999-650-607 959999-651-608 959999-652-609 959999-653-610 959999-654-611 959999-655-612 959999-656-613 959999-657-614 959999-658-615 959999-659-616 959999-660-617 959999-661-618 959999-662-619 959999-663-620 959999-664-621 959999-665-622 959999-666-623 959999-667-624 959999-668-625 959999-669-626 959999-670-627 959999-671-628 959999-672-629 959999-673-630 959999-674-631 959999-675-632 959999-676-633 959999-677-634 959999-678-635 959999-679-636 959999-680-637 959999-681-638 959999-682-639 959999-683-640 959999-684-641 959999-685-642 959999-686-643 959999-687-644 959999-688-645 959999-689-646 959999-690-647 959999-691-648 959999-692-649 959999-693-650 959999-694-651 959999-695-652 959999-696-653 959999-697-654 959999-698-655 959999-699-656 959999-700-657 959999-701-658 959999-702-659 959999-703-660 959999-704-661 959999-705-662 959999-706-663 959999-707-664 959999-708-665 959999-709-666 959999-710-667 959999-711-668 959999-712-669 959999-713-670 959999-714-671 959999-715-672 959999-716-673 959999-717-674 959999-718-675 959999-719-676 959999-720-677 959999-721-678 959


10522958-updated

25 of 356




RN 959997-98-9 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 959998-00-6 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-(6-cyano-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 959998-02-8 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


10522958-updated

27 of 356




RN 959998-10-8 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 959998-12-0 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-(6-methyl-3-pyridinyl)-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959998-14-2 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-


10522958-updated

26 of 356




RN 959998-04-0 CAPLUS  
CN 2-Thiophenecarboxamide, 5-(6-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 959998-06-2 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 959998-08-4 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

10522958-updated

28 of 356


piperidinyl)oxy]phenyl]ethoxy]-5-[5-(3-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959998-16-4 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959998-18-6 CAPLUS  
CN 2-Thiophenecarboxamide, 5-(1H-benzimidazol-1-yl)-3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959998-20-0 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.





RN 959998-23-3 CAPLUS  
CN 2-Thiophenecarboxamide, 5-((1H-benzimidazol-1-yl)-3-((1R)-1-(2-chloro-3-(2-(4-morpholinyl)ethoxy)phenyl)ethoxy))- (CA INDEX NAME)

Absolute stereochemistry.




RN 959998-25-5 CAPLUS  
CN 2-Thiophenecarboxamide, 5-((1H-benzimidazol-1-yl)-3-((1R)-1-(2-chloro-3-(2-(1-piperazinyl)ethoxy)phenyl)ethoxy))- (CA INDEX NAME)

Absolute stereochemistry.




RN 959998-31-3 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 959998-33-5 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959998-37-9 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


RN 959998-27-7 CAPLUS  
CN 2-Thiophenecarboxamide, 5-((1H-benzimidazol-1-yl)-3-((1R)-1-(2-chloro-3-(2-(4-methyl-1-piperazinyl)ethoxy)phenyl)ethoxy))- (CA INDEX NAME)

Absolute stereochemistry.




RN 959998-29-9 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




Absolute stereochemistry.




RN 959998-39-1 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959998-41-5 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959998-42-6 CAPLUS  
CN 2-Thiophenecarboxamide, 3-((1R)-1-(2-chloro-3-(2-(4-morpholinyl)ethoxy)phenyl)ethoxy)-5-((1-methyl-1H-pyrazol-4-yl)-1H-

Absolute stereochemistry.




RN 959998-44-8 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959998-47-1 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 959998-49-3 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B


CP3

RN 959998-58-4 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




PAGE 1-A



RN 959998-52-8 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-(2-fluoroethyl))-4-piperidinyl]oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

CH2P

RN 959998-55-1 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


RN 959998-61-9 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 959998-63-1 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959998-67-5 CAPLUS  
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-4-fluoro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 959998-66-4

CMF C10 H30 Cl1 F1 N6 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 959998-70-0 CAPLUS  
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-4-fluoro-3-[(1-(2-fluoroethyl)-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

CH2F

RN 959998-72-2 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 959998-74-4 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959998-76-6 CAPLUS  
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-6-fluoro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959998-82-4 CAPLUS  
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)methoxy]phenyl]ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 959998-84-6 CAPLUS  
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959998-91-5 CAPLUS  
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)methoxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

Me

RN 959998-97-1 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-01-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(2-methyl-4-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-03-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-05-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-08-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-11-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-14-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-17-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-19-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-20-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 959999-21-4 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



10522958-updated


45 of 356



RN 959999-23-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(trifluoromethoxy)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-25-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959999-26-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[6-(trifluoromethoxy)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


46 of 356



RN 959999-27-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-28-1 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5,6-difluoro-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-29-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

10522958-updated


47 of 356



RN 959999-30-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-(5-chloro-6-fluoro-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-31-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959999-32-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-(6-chloro-5-fluoro-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]- (CA INDEX NAME)

10522958-updated

48 of 356


Absolute stereochemistry.



RN 959999-33-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-34-9 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959999-36-1 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 959999-38-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[1-[2-fluoro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 959999-40-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 959999-42-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 959999-44-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 959999-46-3 CAPLUS

2-Thiophenecarboxamide, 3-[[[3-[(1-methyl-4-piperidinyl)oxy]phenyl]methoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]]- (CA INDEX NAME)




RN 959999-47-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 959999-48-5 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



RN 959999-50-9 CAPLUS

25-3-1977-150-5 CAPBOS  
CN 3-(3-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-benzimidazol-1-yl])- (CA INDEX NAME)


Absolute stereochemistry.




1T 660803-39-8P 660870-62-8P 660870-06-4P  
660800-07-5P 660370-08-6P 929695-38-5P  
929095-39-6P 929095-46-5P 929095-62-5P  
929095-63-6P 929095-54-7P 929276-47-1P  
929280-84-2P 929220-86-4P 929280-50-0P

```


559909-77-4P 559909-82-1P 559909-83-2P
559909-84-3P 559909-85-4P 559909-86-5P
559909-87-6P 559909-96-7P 559909-97-8P
559909-98-9P 559910-00-0P 559912-51-0P
559913-52-1P 559913-53-2P 559913-54-3P
559913-55-4P 559913-56-5P 559913-57-6P
559913-58-7P 559913-59-8P 559913-60-9P
559913-61-0P 559913-62-2P 559913-63-4P
559913-70-1P 559913-71-4P 559913-72-5P
559913-76-2P 559913-77-0P 559913-78-1P
559913-79-2P 559913-80-5P 559913-82-7P
559913-83-8P 559913-84-3P 559913-85-0P
559913-87-2P 559913-88-2P 559913-90-7P
559913-91-4P 559913-92-1P 559913-93-0P
559913-94-1P 559913-95-2P 559913-97-4P
559913-98-6P 560000-01-5P 560003-05-0P
560006-05-0P 560007-07-1P 560008-09-3P
560008-10-4P 560008-11-7P 560009-13-5P
560009-14-0P 560009-16-2P 560009-18-4P
560009-19-5P 560009-20-8P 560009-22-0P
560009-24-2P 560009-26-4P 560009-28-6P
560009-29-7P 560009-30-0P 560009-32-2P
560009-33-3P 560009-35-5P 560009-37-7P
560009-38-2P 560009-40-2P 560009-41-3P
560009-42-4P 560009-43-5P 560009-44-6P
560009-46-8P 560009-47-9P 560009-48-0P
560009-50-4P 560009-52-6P 560009-53-7P
560009-55-9P 560009-56-0P 560009-58-2P
560009-59-3P 560009-60-6P 560009-61-7P
560009-62-9P 560009-63-9P 560009-64-0P
560009-65-1P 560009-66-2P 560009-67-5P
560009-68-4P 560009-69-5P 560009-70-8P
560009-71-9P 560009-72-0P 560009-73-1P
560009-74-2P 560009-75-2P 560009-76-4P
560009-77-5P 560009-78-6P 560009-79-7P
560009-80-0P 560009-81-1P 560009-82-2P
560009-83-3P 560009-84-4P 560009-85-5P
560009-86-6P 560009-87-7P 560009-88-8P
560009-89-9P 560009-90-2P 560009-91-3P
560009-92-6P 560009-94-6P 560009-96-6P
560009-97-9P 560009-98-0P 560009-01-5P
560009-02-5P 560009-03-0P 560009-04-1P
560009-05-2P 560009-06-3P 560009-10-9P
560009-11-0P 560009-17-6P 560009-18-7P
560009-24-0P 560009-25-6P 560009-31-6P
560009-32-5P 560009-37-0P 560009-38-1P
560009-39-2P 560009-46-5P 560009-47-6P
560009-48-7P 560009-49-8P 560009-50-9P
560009-51-0P 560009-52-1P 560009-53-2P
560009-54-3P 560009-55-4P 560009-56-5P
560009-57-6P 560009-58-7P 560009-59-8P
560009-60-9P 560009-61-0P 560009-62-1P
560009-63-2P 560009-64-3P 560009-65-4P
560009-66-5P 560009-67-6P 560009-68-7P
560009-69-8P 560009-70-9P 560009-71-0P
560009-72-1P 560009-73-2P 560009-74-3P
560009-75-4P 560009-76-5P 560009-77-6P
560009-78-7P 560009-79-8P 560009-80-9P
560009-81-0P 560009-82-1P 560009-83-2P
560009-84-3P 560009-85-4P 560009-86-5P
560009-87-6P 560009-88-7P 560009-89-8P
560009-90-9P 560009-91-0P 560009-92-1P
560009-93-2P 560009-94-3P 560009-95-4P
560009-96-5P 560009-97-6P 560009-98-7P
560009-99-8P 560009-00-9P 560009-01-0P
560009-02-1P 560009-03-2P 560009-04-3P
560009-05-4P 560009-06-5P 560009-07-6P
560009-08-7P 560009-09-8P 560009-10-9P
560009-11-0P 560009-12-0P 560009-13-1P
560009-14-2P 560009-15-3P 560009-16-4P
560009-17-5P 560009-18-6P 560009-19-7P
560009-20-8P 560009-21-9P 560009-22-0P
560009-23-1P 560009-24-2P 560009-25-3P
560009-26-4P 560009-27-5P 560009-28-6P
560009-29-7P 560009-30-8P 560009-31-9P
560009-32-0P 560009-33-1P 560009-34-2P
560009-35-3P 560009-36-4P 560009-37-5P
560009-38-6P 560009-39-7P 560009-40-8P
560009-41-9P 560009-42-0P 560009-43-1P
560009-44-2P 560009-45-3P 560009-46-4P
560009-47-5P 560009-48-6P 560009-49-7P
560009-50-8P 560009-51-9P 560009-52-0P
560009-53-1P 560009-54-2P 560009-55-3P
560009-56-4P 560009-57-5P 560009-58-6P
560009-59-7P 560009-60-8P 560009-61-9P
560009-62-0P 560009-63-1P 560009-64-2P
560009-65-3P 560009-66-4P 560009-67-5P
560009-68-6P 560009-69-7P 560009-70-8P
560009-71-9P 560009-72-0P 560009-73-1P
560009-74-2P 560009-75-3P 560009-76-4P
560009-77-5P 560009-78-6P 560009-79-7P
560009-80-8P 560009-81-9P 560009-82-0P
560009-83-1P 560009-84-2P 560009-85-3P
560009-86-4P 560009-87-5P 560009-88-6P
560009-89-7P 560009-90-8P 560009-91-9P
560009-92-0P 560009-93-1P 560009-94-2P
560009-95-3P 560009-96-4P 560009-97-5P
560009-98-6P 560009-99-7P 560009-00-8P
560009-01-9P 560009-02-0P 560009-03-1P
560009-04-2P 560009-05-3P 560009-06-4P
560009-07-5P 560009-08-6P 560009-09-7P
560009-10-8P 560009-11-9P 560009-12-0P
560009-13-1P 560009-14-2P 560009-15-3P
560009-16-4P 560009-17-5P 560009-18-6P
560009-19-7P 560009-20-8P 560009-21-9
```




RN 660870-00-8 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-(6-chloro-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)




RN 660870-06-4 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)



RN 660870-07-5 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-(6-bromo-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)




RN 660870-08-6 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-(5,6-dichloro-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)




RN 929095-38-5 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-[(2,2-dimethyl-1-oxopropoxy)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-39-6 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-(hydroxymethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-46-5 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-(6-bromo-1H-benzimidazol-1-yl)-3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-, methyl ester (CA INDEX NAME)




RN 929095-62-5 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(2,2-dimethyl-1-oxopropoxy)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-63-6 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(hydroxymethyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-64-7 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 929276-47-1 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 929280-84-2 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 929280-86-4 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 929280-90-0 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 959909-77-4 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-([(1,1-dimethylethyl)dimethylsilyl]oxy)-, methyl ester (CA INDEX NAME)



RN 959909-82-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-[(1,1-dimethylethyl)dimethylsilyl]oxy)phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959909-83-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-

chloro-3-[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-84-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-85-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-86-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-3-[(1R)-1-(3-(2-bromoethoxy)-2-chlorophenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-87-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chloro-3-hydroxyphenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-96-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-nitrophenyl]ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959909-97-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chloro-3-nitrophenyl]ethoxy]-5-(5,6-

dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-98-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(3-amino-2-chlorophenyl]ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959910-00-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(3-(2-bromoethoxy)-2-chlorophenyl]ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-51-0 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-(5-chloro-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-

10522958-updated 61 of 356  
chloro-3-hydroxyphenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999 52-1 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-(5-chloro-1H-benzimidazol-1-yl)-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester (CA INDEX NAME)




RN 959999 53-2 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[[[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-(6-cyano-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999 54-3 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-(5-cyano-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)

10522958-updated 62 of 356




RN 959999 55-4 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-(6-cyano-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)



RN 959999 56-5 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-(6-cyano-1H-benzimidazol-1-yl)-3-[[[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959999 57-6 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[[[(1R)-1-[2-chloro-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]ethoxy]-5-(6-cyano-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.

10522958-updated 63 of 356




RN 959999 58-7 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-(6-bromo-1H-benzimidazol-1-yl)-3-[[[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 959999 59-8 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-(6-bromo-1H-benzimidazol-1-yl)-3-[[[(1R)-1-(2-chloro-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959999 60-1 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[[[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-(6-methyl-3-pyridinyl)-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.

10522958-updated 64 of 356




RN 959999 61-2 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[[[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-(6-methyl-3-pyridinyl)-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999 62-3 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 959999 63-4 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-70-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[(2-methyl-4-pyridinyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 959999-71-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(6-chloro-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)



RN 959999-79-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-80-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[5-(trifluoromethoxy)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-82-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[5-(trifluoromethoxy)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

RN 959999-72-5 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-(6-chloro-1H-benzimidazol-1-yl)-3-[(1,1-dimethylethyl)dimethylsilyloxy]-, methyl ester (CA INDEX NAME)



RN 959999-76-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 959999-77-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-78-1 CAPLUS



RN 959999-83-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-[(1,1-dimethylethyl)dimethylsilyloxy]phenyl)ethoxy]-5-[5-(trifluoromethoxy)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-84-9 CAPLUS


CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[5,6-difluoro-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 959999-85-0 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-(5,6-difluoro-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)



RN 959999-87-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[(1R)-1-[[5-(5-bromo-1H-benzimidazol-1-yl)-2-(methoxycarbonyl)-3-thienyl]oxy]ethyl]-2-chlorophenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-88-3 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 959999-90-7 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 1-[4-(hydroxy-5-(methoxycarbonyl)-2-thienyl)-, 2-propen-1-yl ester (CA INDEX NAME)



RN 959999-94-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 959999-95-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(6-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-97-4 CAPLUS



RN 959999-91-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-, 2-propen-1-yl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-92-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-(6-cyano-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-93-0 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[5-(6-cyano-1H-benzimidazol-1-yl)-2-(methoxycarbonyl)-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



CN 1-Piperidinecarboxylic acid, 4-[3-[(1R)-1-[[5-(6-bromo-1H-benzimidazol-1-yl)-2-(methoxycarbonyl)-3-thienyl]oxy]ethyl]-2-chlorophenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-99-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 960000-01-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[5-(5-chloro-1H-benzimidazol-1-yl)-2-(methoxycarbonyl)-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.





PAGE 1-B

RN 960000-03-7 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

-OBu-t

RN 960000-07-1 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


PAGE 1-A



RN 960000-05-9 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-[5-(6-methyl-3-pyridinyl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

-OBu-t

RN 960000-09-3 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(3-pyridinyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-10-6 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-[5-(3-pyridinyl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.


RN 960000-11-7 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 960000-12-8 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[(1H-benzimidazol-1-yl)-3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.






RN 960000-14-0 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-{3-[(1R)-1-[[5-(1H-benzimidazol-1-yl)-2-(methoxycarbonyl)-3-thienyl]oxy]ethyl]-2-chlorophenoxy}-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 960000-16-2 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 960000-18-4 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-{1H-benzimidazol-1-yl}-3-[(1R)-1-[2-chloro-3-[(4-morpholinyl)ethoxy]phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 960000-24-2 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(6-fluoro-3-pyridinyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-26-4 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(6-fluoro-3-pyridinyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-19-5 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[2-{3-[(1R)-1-[[5-(1H-benzimidazol-1-yl)-2-(methoxycarbonyl)-3-thienyl]oxy]ethyl]-2-chlorophenoxy}ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-20-8 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 960000-22-0 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-{1H-benzimidazol-1-yl}-3-[(1R)-1-[2-chloro-3-[(4-methyl-1-piperazinyl)ethoxy]phenyl]ethoxy]-, methyl ester (CA INDEX NAME)




RN 960000-28-6 CAPLUS  
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(6-fluoro-3-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 960000-29-7 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



10522958-updated 81 of 356


RN 960000-30-0 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 960000-32-2 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 960000-33-3 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 960000-35-5 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[3-(2-bromoethoxy)-2-

10522958-updated 82 of 356


chlorophenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 960000-37-7 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[(2-(4-morpholinyl)ethoxy]phenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 960000-39-9 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[3-(2-bromoethoxy)-2-chlorophenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.

10522958-updated 83 of 356




RN 960000-40-2 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 960000-41-3 CAPLUS  
CN 4-Morpholinecarboxylic acid, 2-[(2-chloro-3-[(1R)-1-[5-[5-chloro-1H-benzimidazol-1-yl]-2-(methoxycarbonyl)-3-thienyl]oxy]ethyl]phenoxy)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 960000-42-4 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

10522958-updated 84 of 356



RN 960000-43-5 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[(2-(4-chlorophenyl)ethoxy]phenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

CH2F

RN 960000-44-6 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 960000-46-8 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[5-chloro-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-chloro-4-fluoro-3-hydroxyphenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 960000-47-9 CAPLUS

PAGE 1-A




PAGE 1-B



RN 960000-52-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 960000-53-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-4-fluoro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 960000-48-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-4-fluoro-3-hydroxyphenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-50-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-chloro-6-fluoro-3-[(1R)-1-[(2-methoxycarbonyl)-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-55-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-4-fluoro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 960000-56-0 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[(2-(methoxycarbonyl)-5-[5-(4-pyridinyl)-1H-benzimidazol-1-yl]-3-thienyl)oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 960000-58-2 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 960000-59-3 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

CN 2-Thiophenecarboxylic acid, 3-[1-(2-chloro-6-fluoro-3-[(1-methyl-4-piperidinyl)oxy]phenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)





RN 960000-62-8 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[(5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-2-(methoxycarbonyl)-3-thienyl)oxy]ethyl]phenoxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-63-9 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



OBu-t


RN 960000-60-6 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[1-(2-chloro-6-fluoro-3-hydroxyphenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)



RN 960000-61-7 CAPLUS

RN 960000-64-0 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[(2-(methoxycarbonyl)-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-thienyl)oxy]ethyl]phenoxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




OBu-t

RN 960000-65-1 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[(2-(methoxycarbonyl)-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-thienyl)oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B

-OBu-t


RN 960000-66-2 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-[(2-methyl-4-pyridinyl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-70-8 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[5-(6-chloro-1H-benzimidazol-1-yl)-2-(methoxycarbonyl)-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 960000-71-9 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 960000-72-0 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-[(2-methyl-4-pyridinyl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


RN 960000-67-3 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 960000-68-4 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-[5-bromo-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-69-6 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-[5-bromo-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

-OBu-t


RN 960000-73-1 CAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[2-chloro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-[[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]methyl]-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-74-2 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 960000-75-3 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[5-(methylthio)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 960000-76-4 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[6-(methylthio)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 960000-77-5 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[5-(methylthio)-1H-benzimidazol-1-yl]-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 960000-78-6 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-(methylthio)-1H-benzimidazol-1-yl]-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 960000-79-7 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[5-(methylsulfonyl)-1H-benzimidazol-1-yl]-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 960000-80-0 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-(methylsulfonyl)-1H-benzimidazol-1-yl]-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 960000-81-1 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[5-(methylsulfonyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 960000-82-2 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[6-(methylsulfonyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 960000-83-3 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[[[1R]-1-[2-chloro-3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]phenyl]ethoxy]-5-[5-(methylsulfonyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-84-4 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[[[1R]-1-[2-chloro-3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]phenyl]ethoxy]-5-[6-(methylsulfonyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-85-5 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[[[1R]-1-[2-chloro-3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]phenyl]ethoxy]-5-[5-(methylsulfonyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-86-6 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[[[1R]-1-[2-chloro-3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]phenyl]ethoxy]-5-[6-(methylsulfonyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 960000-87-7 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[[[1R]-1-[[2-(methoxycarbonyl)-5-(methylsulfonyl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 960000-88-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-[6-(methylsulfonyl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



Absolute stereochemistry.



RN 960000-84-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 960000-94-6 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-(5-chloro-6-fluoro-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chlorophenyl)ethoxy], methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 960000-96-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5-chloro-6-fluoro-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)



RN 960000-97-9 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

RN 960000-90-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 960000-91-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-[5-(trifluoromethoxy)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 960000-92-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(trifluoromethoxy)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 960000-98-0 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-(5-chloro-6-fluoro-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960001-01-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(6-chloro-5-fluoro-1H-benzimidazol-1-yl)-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 960001-02-9 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-(6-chloro-5-fluoro-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)



RN 960001-03-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(6-chloro-5-fluoro-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 960001-04-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 960001-05-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 960001-06-3 CAPLUS




RN 960001-18-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 960001-24-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-{[4-{1-[[2-(methoxycarbonyl)-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]-2-pyrimidinyl]oxy}-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 960001-25-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-(5,6-dichloro-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960001-10-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 960001-11-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 960001-17-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-{[2-fluoro-3-{1-[[2-(methoxycarbonyl)-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy}-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 960001-31-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-{[4-{1-[[2-(methoxycarbonyl)-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]-2-pyridinyl]oxy}-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 960001-32-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 960001-37-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-{[6-{1-[[2-(methoxycarbonyl)-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]-2-pyridinyl]oxy}-, 1,1-dimethylethyl ester (CA INDEX NAME)




10522958-updated


109 of 356



RN 960001-39-1 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED




RN 960001-39-2 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[3-[[2-(methoxycarbonyl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]methyl]phenoxyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 960001-40-5 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

10522958-updated


110 of 356



RN 960001-43-8 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[2-[(1-[[2-(methoxycarbonyl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]-4-pyridinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 960001-44-9 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED




RN 960001-45-0 CAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-, 2-acetylhydrazide (CA INDEX NAME)

Absolute stereochemistry.


10522958-updated

111 of 356




RN 960001-47-2 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 960001-49-3 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 960001-50-7 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]ethoxyl]-5-[5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.


10522958-updated

112 of 356




RN 960001-51-8 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 960001-53-0 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[2-chloro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



Absolute stereochemistry.




— OBU-t

RN 960001-55-2 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



IT 113387-85-2, Methyl 5-(1H-benzimidazol-1-yl)-3-hydroxy-thiophene-2-carboxylate 660870-09-7  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(starting material; preparation of benzimidazolylthiophene compds. useful in treatment of diseases)  
RN 113387-85-2 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)



RN 660870-09-7 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)




X L6 ANSWER 3 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2007:819365 CAPLUS [Full-text](#)  
DN 147:359215  
TI Pharmacological and Functional Comparison of the Polo-like Kinase Family: Insight into Inhibitor and Substrate Specificity  
AU Johnson, Eric F.; Stewart, Kent D.; Woods, Keith M.; Giranda, Vincent L.; Luo, Yan  
CS Cancer Research, Abbott Laboratories, Abbott Park, IL, 60064, USA

— OBU-t

RN 960002-40-8 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[6-(trifluoromethoxy)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



IT 960001-63-2P  
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prophetic intermediate; preparation of benzimidazolylthiophene compds. useful in treatment of diseases)  
RN 960001-63-2 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[(1,1-dimethylethyl)diphenylsilyloxy]-6-fluorophenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

SO [Biochemistry \(2007\)](#), 46(33), 9551-9563 - NOT ODP/NOT PRIOR ART  
CODEN: BICHAW; ISSN: 0006-2960  
PB American Chemical Society  
DT Journal  
LA English  
AB PLK1 (polo-like kinase 1) is a key mitotic kinase and a therapeutic target in the treatment of proliferative diseases. Here we investigate the relative substrate specificity and pharmacol. relatedness of PLK1, -2, -3, and -4 that together comprise a conserved family of Ser/Thr kinases (PLK family). We report consensus substrate sequences for PLK2, -3, and -4 and an expanded consensus sequence for PLK1, which we use to design an optimal peptide substrate, PLKtide. We report inhibitory activity for the entire PLK family across a diverse set of small-mol. ATP-competitive inhibitors including several clin. compds. With respect to both substrate and ATP-site specificity, highest similarity is observed between PLK2 and PLK3, PLK1 is next most similar, and PLK4 is least similar. Further, we have identified and report time-dependent inhibition by two potent and selective PLK inhibitors.  
IT 660868-91-7  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(insight into inhibitor and substrate specificity of polo-like kinase family)  
RN 660868-91-7 CAPLUS  
CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethyl)phenyl)methoxy]- (CA INDEX NAME)



RE.CNT 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 4 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2007:284227 CAPLUS [Full-text](#)  
DN 146:337892  
TI Regioselective process for preparing benzimidazole thiophenes  
IN Hornberger, Keith; Cheung, Mui; Pobanz, Mark Andrew; Emmite, Kyle Allen; Kuntz, Kevin Wayne; Badiang, Jennifer Gabriel  
PA Smithkline Beecham Corporation, USA  
SO PCT Int. Appl., 31pp.  
CODEN: PIXX2  
DT Patent  
LA English  
FAN.CNT 1  
PATENT NO. KIND DATE APPLICATION NO. DATE  
(NOT ODP)  
PI WO 2007030366 A1 20070315 WO 2006-083793 20060828



M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MM, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BM, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRA1 US 2005-714301P P 20050906 - NOT PRIOR ART

OS MARPAT 146:337892


GI



AB The present invention provides a process for preparing benzimidazole thiophene compds. of formula I [R1 = H, alkyl, alkenyl, etc.; Q1 = -(R2)a(Y1)b(R2)cR3; a, b and c independently = 0 or 1 and at least one of a or b = 1; n = 0-3; each Q2 independently = -(R2)aa(Y2)bb(R2)ccR4; or two adjacent Q2 together form a cyclic or heterocyclic ring optionally substituted; aa, bb and cc independently = 0 or 1; each Y1 and Y2 independently = O, CO, CO2, etc.; each R2 independently = alkylene, alkenylene and alkynylene; each R3 and R4 independently = H, halo, alkynyl, etc.; R5 = H, halo, cycloalkyl, etc.]. Thus, e.g., II was prepared by substitution of 2-bromo-4-((4-(methyloxy)phenyl)methyl)oxy)-1-nitrobenzene (preparation given) with Me 5-amino-3-((1R)-1-[2-(trifluoromethyl)phenyl]ethoxy)-2-thiophene carboxylate (preparation given) followed by nitro group reduction, cyclization with tri-Me orthoformate to form benzimidazole core, and deprotection. The processes of the instant invention produce the desired regioisomer via a more direct and efficient route, utilizing less resources and leading to a better yield. Intermediates used in the process are also claimed. Pharmaceutical compns. and therapeutic uses for I were described in prior patent (PCT Publication NO. WO04/014899; published 19 Feb. 2004).

IT 5-179-51-25 22-173-54-1F

RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (regioselective process for preparing benzimidazole thiophenes)



IT 112377-85-2P 640937-51-2F 629040-09-5P

629040-11-2P 629040-24-4F 629040-25-5P

629040-26-6P 629040-28-8P 629040-30-0P

629040-31-1P 629040-32-2P 629040-33-3P

629040-34-4P 629040-35-5P 629040-36-6P

629040-37-7P 629040-38-8P 629040-39-9P

629040-40-0P 629040-41-1P 629040-42-2P

629040-43-3P 629040-44-4P 629040-45-5P

629040-46-6P 629040-47-7P 629040-48-8P

629040-49-9P 629040-50-0P 629040-51-1P

629040-52-2P 629040-53-3P 629040-54-4P

629040-55-5P 629040-56-6P 629040-57-7P

629040-58-8P 629040-59-9P 629040-60-0P

629040-61-1P 629040-62-2P 629040-63-3P

629040-64-4P 629040-65-5P 629040-66-6P

629040-67-7P 629040-68-8P 629040-69-9P

629040-70-0P 629040-71-1P 629040-72-2P

629040-73-3P 629040-74-4P 629040-75-5P

629040-76-6P 629040-77-7P 629040-78-8P

629040-79-9P 629040-80-0P 629040-81-1P

629040-82-2P 629040-83-3P 629040-84-4P

629040-85-5P 629040-86-6P 629040-87-7P

629040-88-8P 629040-89-9P 629040-90-0P

629040-91-1P 629040-92-2P 629040-93-3P

629040-94-4P 629040-95-5P 629040-96-6P

629040-97-7P 629040-98-8P 629040-99-9P

629040-100-0P 629040-101-1P 629040-102-2P

629040-103-3P 629040-104-4P 629040-105-5P

629040-106-6P 629040-107-7P 629040-108-8P

629040-109-9P 629040-110-0P 629040-111-1P

629040-112-2P 629040-113-3P 629040-114-4P

629040-115-5P 629040-116-6P 629040-117-7P

629040-118-8P 629040-119-9P 629040-120-0P

629040-121-1P 629040-122-2P 629040-123-3P

629040-124-4P 629040-125-5P 629040-126-6P

629040-127-7P 629040-128-8P 629040-129-9P

629040-130-0P 629040-131-1P 629040-132-2P

629040-133-3P 629040-134-4P 629040-135-5P

629040-136-6P 629040-137-7P 629040-138-8P

629040-139-9P 629040-140-0P 629040-141-1P

629040-142-2P 629040-143-3P 629040-144-4P

629040-145-5P 629040-146-6P 629040-147-7P

629040-148-8P 629040-149-9P 629040-150-0P

629040-151-1P 629040-152-2P 629040-153-3P

629040-154-4P 629040-155-5P 629040-156-6P

629040-157-7P 629040-158-8P 629040-159-9P

629040-160-0P 629040-161-1P 629040-162-2P

629040-163-3P 629040-164-4P 629040-165-5P

629040-166-6P 629040-167-7P 629040-168-8P

629040-169-9P 629040-170-0P 629040-171-1P

629040-172-2P 629040-173-3P 629040-174-4P

629040-175-5P 629040-176-6P 629040-177-7P

629040-178-8P 629040-179-9P 629040-180-0P

629040-181-1P 629040-182-2P 629040-183-3P

629040-184-4P 629040-185-5P 629040-186-6P

629040-187-7P 629040-188-8P 629040-189-9P

629040-190-0P 629040-191-1P 629040-192-2P

629040-193-3P 629040-194-4P 629040-195-5P

629040-196-6P 629040-197-7P 629040-198-8P

629040-199-9P 629040-200-0P 629040-201-1P

629040-202-2P 629040-203-3P 629040-204-4P

629040-205-5P 629040-206-6P 629040-207-7P

629040-208-8P 629040-209-9P 629040-210-0P

629040-211-1P 629040-212-2P 629040-213-3P

629040-214-4P 629040-215-5P 629040-216-6P

629040-217-7P 629040-218-8P 629040-219-9P

629040-220-0P 629040-221-1P 629040-222-2P

629040-223-3P 629040-224-4P 629040-225-5P

629040-226-6P 629040-227-7P 629040-228-8P

629040-229-9P 629040-230-0P 629040-231-1P

629040-232-2P 629040-233-3P 629040-234-4P

629040-235-5P 629040-236-6P 629040-237-7P

629040-238-8P 629040-239-9P 629040-240-0P

629040-241-1P 629040-242-2P 629040-243-3P

629040-244-4P 629040-245-5P 629040-246-6P

629040-247-7P 629040-248-8P 629040-249-9P

629040-250-0P 629040-251-1P 629040-252-2P

629040-253-3P 629040-254-4P 629040-255-5P

629040-256-6P 629040-257-7P 629040-258-8P

629040-259-9P 629040-260-0P 629040-261-1P

629040-262-2P 629040-263-3P 629040-264-4P

629040-265-5P 629040-266-6P 629040-267-7P

629040-268-8P 629040-269-9P 629040-270-0P

629040-271-1P 629040-272-2P 629040-273-3P

629040-274-4P 629040-275-5P 629040-276-6P

629040-277-7P 629040-278-8P 629040-279-9P

629040-280-0P 629040-281-1P 629040-282-2P

629040-283-3P 629040-284-4P 629040-285-5P

629040-286-6P 629040-287-7P 629040-288-8P

629040-289-9P 629040-290-0P 629040-291-1P

629040-292-2P 629040-293-3P 629040-294-4P

629040-295-5P 629040-296-6P 629040-297-7P

629040-298-8P 629040-299-9P 629040-300-0P

629040-301-1P 629040-302-2P 629040-303-3P

629040-304-4P 629040-305-5P 629040-306-6P

629040-307-7P 629040-308-8P 629040-309-9P

629040-310-0P 629040-311-1P 629040-312-2P

629040-313-3P 629040-314-4P 629040-315-5P

629040-316-6P 629040-317-7P 629040-318-8P

629040-319-9P 629040-320-0P 629040-321-1P

629040-322-2P 629040-323-3P 629040-324-4P

629040-325-5P 629040-326-6P 629040-327-7P

629040-328-8P 629040-329-9P 629040-330-0P

629040-331-1P 629040-332-2P 629040-333-3P

629040-334-4P 629040-335-5P 629040-336-6P

629040-337-7P 629040-338-8P 629040-339-9P

629040-340-0P 629040-341-1P 629040-342-2P

629040-343-3P 629040-344-4P 629040-345-5P

629040-346-6P 629040-347-7P 629040-348-8P

629040-349-9P 629040-350-0P 629040-351-1P

629040-352-2P 629040-353-3P 629040-354-4P

629040-355-5P 629040-356-6P 629040-357-7P

629040-358-8P 629040-359-9P 629040-360-0P

629040-361-1P 629040-362-2P 629040-363-3P

629040-364-4P 629040-365-5P 629040-366-6P

629040-367-7P 629040-368-8P 629040-369-9P

629040-370-0P 629040-371-1P 629040-372-2P

629040-373-3P 629040-374-4P 629040-375-5P

629040-376-6P 629040-377-7P 629040-378-8P

629040-379-9P 629040-380-0P 629040-381-1P

629040-382-2P 629040-383-3P 629040-384-4P

629040-385-5P 629040-386-6P 629040-387-7P

629040-388-8P 629040-389-9P 629040-390-0P

629040-391-1P 629040-392-2P 629040-393-3P

629040-394-4P 629040-395-5P 629040-396-6P

629040-397-7P 629040-398-8P 629040-399-9P

629040-400-0P 629040-401-1P 629040-402-2P

629040-403-3P 629040-404-4P 629040-405-5P

629040-406-6P 629040-407-7P 629040-408-8P

629040-409-9P 629040-410-0P 629040-411-1P

629040-412-2P 629040-413-3P 629040-414-4P

629040-415-5P 629040-416-6P 629040-417-7P

629040-418-8P 629040-419-9P 629040-420-0P

629040-421-1P 629040-422-2P 629040-423-3P

629040-424-4P 629040-425-5P 629040-426-6P

629040-427-7P 629040-428-8P 629040-429-9P

629040-430-0P 629040-431-1P 629040-432-2P

629040-433-3P 629040-434-4P 629040-435-5P

629040-436-6P 629040-437-7P 629040-438-8P

629040-439-9P 629040-440-0P 629040-441-1P

629040-442-2P 629040-443-3P 629040-444-4P

629040-445-5P 629040-446-6P 629040-447-7P

629040-448-8P 629040-449-9P 629040-450-0P

629040-451-1P 629040-452-2P 629040-453-3P

629040-454-4P 629040-455-5P 629040-456-6P

629040-457-7P 629040-458-8P 629040-459-9P

629040-460-0P 629040-461-1P 629040-462-2P

629040-463-3P 629040-464-4P 629040-465-5P

629040-466-6P 629040-467-7P 629040-468-8P

629040-469-9P 629040-470-0P 629040-471-1P

629040-472-2P 629040-473-3P 629040-474-4P

629040-475-5P 629040-476-6P 629040-477-7P

629040-478-8P 629040-479-9P 629040-480-0P

629040-481-1P 629040-482-2P 629040-483-3P

629040-484-4P 629040-485-5P 629040-486-6P

629040-487-7P 629040-488-8P 629040-489-9P

629040-490-0P 629040-491-1P 629040-492-2P

629040-493-3P 629040-494-4P 629040-495-5P

629040-496-6P 629040-497-7P 629040-498-8P

629040-499-9P 629040-500-0P 629040-501-1P

629040-502-2P 629040-503-3P 629040-504-4P

629040-505-5P 629040-506-6P 629040-507-7P

629040-508-8P 629040-509-9P 629040-510-0P

629040-511-1P 629040-512-2P 629040-513-3P

629040-514-4P 629040-515-5P 629040-516-6P

629040-517-7P 629040-518-8P 629040-519-9P

629040-520-0P 629040-521-1P 629040-522-2P

629040-523-3P 629040-524-4P 629040-525-5P

629040-526-6P 629040-527-7P 629040-528-8P

629040-529-9P 629040-530-0P 629040-531-1P

629040-532-2P 629040-533-3P 629040-534-4P

629040-535-5P 629040-536-6P 629040-537-7P

629040-538-8P 629040-539-9P 629040-540-0P

629040-541-1P 629040-542-2P 629040-543-3P

629040-544-4P 629040-545-5P 629040-546-6P

629040-547-7P 629040-548-8P 629040-549-9P

629040-550-0P 629040-551-1P 629040-552-2P

629040-553-3P 629040-554-4P 629040-555-5P

629040-556-6P 629040-557-7P 629040-558-8P

629040-559-9P 629040-560-0P 629040-561-1P

629040-562-2P 629040-563-3P 629040-564-4P

629040-565-5P 629040-566-6P 629040-567-7P

629040-568-8P 629040-569-9P 629040-570-0P

629040-571-1P 629040-572-2P 629040-573-3P

629040-574-4P 629040-575-5P 629040-576-6P

629040-577-7P 629040-578-8P 629040-579-9P

629040-580-0P 629040-581-1P 629040-582-2P

629040-583-3P 629040-584-4P 629040-585-5P

629040-586-6P 629040-587-7P 629040-588-8P

629040-589-9P 629040-590-0P 629040-591-1P

629040-592-2P 629040-593-3P 629040-594-4P

629040-595-5P 629040-596-6P 629040-597-7P

629040-598-8P 629040-599-9P 629040-600-0P

629040-601-1P 629040-602-2P 629040-603-3P

629040-604-4P 629040-605-5P 629040-606-6P

629040-607-7P 629040-608-8P 629040-609-9P

629040-610-0P 629040-611-1P 629040-612-2P

629040-613-3P 629040-614-4P 629040-615-5P

629040-616-6P 629040-617-7P 629040-618-8P

629040-619-9P 629040-620-0P 629040-621-1P

629040-622-2P 629040-623-3P 629040-624-4P

629040-625-5P 629040-626-6P 629040-627-7P

629040-628-8P 629040-629-9P 629040-630-0P

629040-631-1P 629040-632-2P 629040-633-3P

629040-634-4P 629040-635-5P 629040-636-6P

629040-637-7P 629040-638-8P 629040-639-9P

629040-640-0P 629040-641-1P 629040-642-2P

629040-643-3P 629040-644-4P 629040-645-5P

629040-646-6P 629040-647-7P 629040-648-8P

629040-649-9P 629040-650-0P 629040-651-1P

629040-652-2P 629040-653-3P 629040-654-4P

629040-655-5P 629040-656-6P 629040-657-7P

629040-658-8P 629040-659-9P 629040-660-0P

629040-661-1P 629040-662-2P 629040-663-3P

629040-664-4P 629040-665-5P 629040-666-6P

629040-667-7P 629040-668-8P 629040-669-9P

629040-670-0P 629040-671-1P 629040-672-2P

629040-673-3P 629040-674-4P 629040-675-5P

629040-676-6P 629040-677-7P 629040-678-8P

629040-679-9P 629040-680-0P 629040-681-1P

629040-682-2P 629040-683-3P 629040-684-4P

629040-685-5P 629040-686-6P 629040-687-7P

629040-688-8P 629040-689-9P 629040-690-0P

629040-691-1P 629040-692-2P 629040-693-3P

629040-694-4P 629040-695-5P 629040-696-6P

629040-697-7P 629040-698-8P 629040-699-9P

629040-700-0P 629040-701-1P 629040-702-2P

629040-703-3P 629040-704-4P 629040-705-5P


629040-706-6P 629040-707-7P 629040-708-8P

629040-709-9P 629040-710-0P 629040-711-1P

629040-


10522958-updated

121 of 356



RN 929040-11-9 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[5-[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-14-2 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[5-[1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.


10522958-updated

122 of 356




RN 929040-18-6 CAPLUS  
 CN 2-Thiophenecarboxamide, 5-[5-(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929040-21-1 CAPLUS  
 CN 2-Thiophenecarboxamide, 5-[5-(2-fluoro-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




10522958-updated

123 of 356


RN 929040-24-4 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929040-25-5 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-[5-[2-[(diphenylmethylene)amino]-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-26-6 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-[5-(2-amino-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.


10522958-updated

124 of 356




RN 929040-28-8 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929040-32-4 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-[5-(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-33-5 CAPLUS

10522958-updated

125 of 356

CN 2-Thiophenecarboxamide, 5-[(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chlorophenyl)ethoxy]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-37-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-38-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


126 of 356



RN 929040-40-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-41-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-[3-(4-ethyl-1-piperazinyl)propyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


127 of 356



RN 929095-16-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-38-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(2,2-dimethyl-1-oxopropoxy)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-39-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(hydroxymethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]]-, methyl ester (CA INDEX NAME)

10522958-updated

128 of 356


Absolute stereochemistry.



RN 929095-41-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(methylthio)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-42-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(methylthio)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-43-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-44-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylthio)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-48-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(6-ethenyl-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-49-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(1,2-dihydroxyethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-56-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-5-[6-[(trifluoromethyl)sulfonyl]oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-59-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(dimethoxymethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-62-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(2,2-dimethyl-1-oxopropoxy)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-50-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-51-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-55-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(6-hydroxy-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-63-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(hydroxymethyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-66-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-67-0 CAPLUS


CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(6-hydroxy-

Absolute stereochemistry.




RN 929095-71-6 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-methoxyphenyl)methoxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-74-9 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(methoxycarbonyl)-4-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-75-0 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-76-1 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-77-2 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-78-3 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-[(1-methyl-4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-79-4 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyloxy)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929276-44-8 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(2-fluoro-4-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-47-1 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 929276-48-2 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[1-[4-hydroxy-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 929276-91-5 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(difluoro-4-piperidinylmethyl)-1H-benzimidazol-1-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CH 1

CRN 929276-90-4  
CMF C26 H25 Cl F2 N4 O2 S






Absolute stereochemistry.



RN 929278-56-8 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(4,4,5,5-tetramethyl-1,3,2 dioxaborolan-2-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929278-73-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[1-[5-(methoxycarbonyl)-4-[(2-(trimethylsilyl)ethoxy]-2-thienyl)-1H-benzimidazol-6-yl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 929278-95-5 CAPLUS

CN 4-Morpholinecarboxylic acid, 2 [[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-97-7 CAPLUS

CN 4-Morpholinecarboxylic acid, 2-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 929279-04-9 CAPLUS


CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[1,1-dimethylethyl]diphenylsilyl]oxy]-1-[2-[[[1,1-dimethylethyl]diphenylsilyl]oxy]ethyl]propoxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 929278-78-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-ethyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-81-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 929278-83-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-06-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[3-hydroxy-1-(2-hydroxyethyl)propoxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-08-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[[[3-chloro-1-(2-chloroethyl)propoxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929279-10-7 CAPLUS


CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[1-

10522958-updated

145 of 356

cyclopentyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-12-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[3-(hydroxy-1-(2-hydroxyethyl)propoxy)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-13-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(7-bromo-6-hydroxy-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929279-15-2 CAPLUS

10522958-updated

146 of 356

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(5,7-dibromo-6-hydroxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-17-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(7-bromo-1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929279-19-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-7-bromo-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


147 of 356



RN 929279-21-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-5,7-dibromo-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-23-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-5,7-dibromo-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




10522958-updated

148 of 356

RN 929279-35-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-bromo-6-[(4-methoxyphenyl)methoxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-37-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5-bromo-6-hydroxy-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-39-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(5-bromo-1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-41-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-5-bromo-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-43-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-55-0 CAPLUS

CN 1H-Azopine-1-carboxylic acid, hexahydro-4-[[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-61-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[cis-4-(1,3-dihydro-1,3-dioxo-2H-isindol-2-yl)cyclohexyl]oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929279-66-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]methyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-45-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-6-(4-piperidinylthio)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-47-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(6-hydroxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)



Absolute stereochemistry.



RN 929279-49-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-(6-hydroxy-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-68-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]methyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-70-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-piperidinylsulfonyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-72-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(3-hydroxypropyl)thio]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-74-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[1R]-1-(2-chlorophenyl)ethoxy]-5-[6-[[3-(hydroxypropyl)sulfonyl]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-76-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[1R]-1-(2-chlorophenyl)ethoxy]-5-[6-[[3-[(methylsulfonyl)oxy]propyl)sulfonyl]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929279-78-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[1R]-1-(2-chlorophenyl)ethoxy]-5-[6-[[3-[(dimethylamino)propyl)sulfonyl]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

RN 929279-83-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(aminomethyl)-1H-benzimidazol-1-yl]-3-[[1R]-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-00-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[[1R]-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-03-5 CAPLUS


CN 2-Thiophenecarboxylic acid, 3-[[1R]-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-79-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[1R]-1-(2-chlorophenyl)ethoxy]-5-[6-[(sulfomethyl)-1H-benzimidazol-1-yl]-, 2-methyl ester, sodium salt (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 929279-81-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[1R]-1-(2-chlorophenyl)ethoxy]-5-[6-[[[(methylamino)sulfonyl]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-06-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[[[(2-hydroxyethyl)thio]methyl]-1H-benzimidazol-1-yl]-3-[[1R]-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-08-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[[[(2-hydroxyethyl)thio]methyl]-1H-benzimidazol-1-yl]-3-[[1R]-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-10-4 CAPLUS


CN 2-Thiophenecarboxamide, 5-[6-[[[(2-hydroxyethyl)sulfonyl]methyl]-1H-benzimidazol-1-yl]-3-[[1R]-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-12-6 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[6-[(ethenylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-14-8 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]difluoromethyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-16-0 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[difluoro(4-piperidinylsulfonyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-18-2 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-(cyanomethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-20-6 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-(cyanomethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-28-4 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[trifluoromethyl]sulfonyl]oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-30-8 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[1-[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]ethenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-32-0 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[1-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]ethenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-34-2 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[1-[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]-1,2-dihydroxyethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-36-4 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-38-6 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-40-0 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]difluoromethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-42-2 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]difluoromethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-44-4 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-46-6 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-[[4-[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-51-3 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-[2-(dimethylamino)ethyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-54-6 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[5-(4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929280-56-0 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[5-(4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-62-6 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[5-(acetyl-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-64-8 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[5-(acetyl-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-66-0 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[5-[(2R)-3-(dimethylamino)-1-oxo-2-propen-1-yl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 929280-68-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[4-[(2-chloro-3-pyridinyl)methoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 929280-70-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[(2-chloro-3-pyridinyl)methoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 929280-72-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(2-chloro-3-pyridinyl)methoxy]-5-[6-(4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)




CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)



RN 929280-88-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chloro-3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-90-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-92-2 CAPLUS

RN 929280-76-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-nitrophenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-78-4 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chloro-3-nitrophenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929280-84-2 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 929280-86-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(2-propen-1-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-94-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(2,3-dihydroxypropyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-96-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(2-(1,3-dioxolan-2-yl)ethyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929280-98-8 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(2-

10522958-updated

169 of 356

oxoethyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-00-5 CAPLUS

CN 2-Thiophenecarboxamide, 3-[[1-[(2-chlorophenyl)ethoxy]-5-[6-(2-hydroxy-2-methoxyethyl)-1H-benzimidazol-1-yl]-2-thienylthio]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-05-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929281-07-2 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-

10522958-updated

170 of 356

(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-09-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-11-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]difluoromethyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




10522958-updated

171 of 356

RN 929281-13-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[[1-[(2-chlorophenyl)ethoxy]-5-[6-(hydroxymethyl)-1H-benzimidazol-1-yl]-2-thienylthio]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-15-2 CAPLUS

CN L-Alanine, N-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-17-4 CAPLUS

CN L-Alanine, N-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




10522958-updated

172 of 356

RN 929281-19-6 CAPLUS

CN L-Valine, N-[[3-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-21-0 CAPLUS

CN L-Alanine, N-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-23-2 CAPLUS

CN L-Alanine, N-[[2-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.






RN 929281-25-4 CAPLUS

CN Carbamic acid, N-[2-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]amino]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-27-6 CAPLUS

CN Carbamic acid, N-[2-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]methylamino]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-29-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-31-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-33-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[[1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(4-piperidinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-36-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-38-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(2-thienyl)-1H-benzimidazol-1-yl]-3-[[1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-40-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(3-pyridinyl)-1H-benzimidazol-1-yl]-3-[[1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-42-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(4-pyridinyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-44-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(phenyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-46-9 CAPLUS


CN 1H-Pyrrole-1-carboxylic acid, 2-[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-48-1 CAPLUS  
CN 1H-Pyrrole-1-carboxylic acid, 2-[(1-[5-(aminocarbonyl)-4-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]-2-thienyl]-1H-benzimidazol-5-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929281-50-5 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[5-(2-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-55-0 CAPLUS  
CN Imidodicarbonic acid, N-[6-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-3-pyridazinyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.


RN 929281-70-9 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-(6-chloro-5-hydroxy-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.





RN 929281-72-1 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-[(4-amino-1-piperidinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-73-2 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-(dimethylamino)-1-piperidinyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-57-2 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(3,5-dimethyl-4-isoxazolyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-68-5 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-chloro-5-[2-(trimethylsilyl)ethoxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-74-3 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(3-methoxy-3-oxopropyl)thio]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-75-4 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(3-methoxy-3-oxopropyl)sulfonyl]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-76-5 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-[(aminosulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-78-7 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 3-{[1R]-1-[[1-[4-{[1R]-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxyethyl}-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)

**Absolute stereochemistry.**



RN 929281-79-8 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[(1R)-1-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]ethyl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)

**Absolute stereochemistry.**



RN 929281 53-4 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]methyl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


10522958-updated

183 of 356

benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA  
INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.  
Double bond geometry as shown.



RN 929288-41-5 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[4-{1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)cyclohexyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


### Absolute stereochemistry.

[illegible]

10522958-updated


182 of 356

### Absolute stereochemistry.




RN 929281-84-5 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

### Absolute stereochemistry.



RN 929288-39-1 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[6-[(2Z)-2-amino-2-(hydroxyimino)ethyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 929288-40-4 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[6-[(2Z)-2-[(acetyloxy)imino]-2-aminoethyl)]-1H-


10522958-updated

184 of 356

929277-06-4F	929277-06-5F	929277-07-6F
929277-08-7F	929277-12-3F	929277-15-6F
929277-18-9F	929277-21-4F	929277-24-7F
929277-26-9F	929277-27-0F	929277-29-2F
929277-32-7F	929277-34-9F	929277-36-1F
929277-40-7F	929277-43-6F	929277-45-1F
929277-47-4F	929277-50-8F	929277-52-1F
929277-55-4F	929277-61-2F	929277-64-5F
929277-67-8F	929277-71-4F	929277-72-5F
929277-73-6F	929277-74-7F	929277-76-9F
929277-78-1F	929277-79-2F	929277-81-6F
929277-83-9F	929277-85-0F	929277-86-1F
929277-87-2F	929277-88-3F	929277-90-7F
929277-92-9F	929277-94-1F	929277-96-3F
929277-98-5F	929278-00-2F	929278-02-5F
929278-04-5F	929278-06-8F	929278-08-0F
929278-10-4F	929278-13-6F	929278-14-8F
929278-16-0F	929278-23-2F	929278-25-1F
929278-27-3F	929278-29-5F	929278-33-2F

RU: SPN (Synthetic preparation); PREP (Preparation)  
 (regioselective process for preparing benzimidazole thiophenes)  
 RN 929040-03-9 CAPLUS  
 CN 2-Thiophenecarboxamide, 5-[5-[6-(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]-3-[1(R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 929040-16-4 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[5-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-benzimidazol-1-yl]-3-{[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]} (CA INDEX NAME)

**Absolute stereochemistry.**

PAGE 1-A





PAGE 2-A




RN 929040-22-2 CAPLUS  
 CN 2-Thiophenecarboxamide, 5-[5-[2-[(1-methyl-4-piperidinyl)amino]-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-34-6 CAPLUS  
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-(1-pyridinyl)-1H-benzimidazol-1-yl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-36-8 CAPLUS  
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-(1-pyridinyl)-1H-benzimidazol-1-yl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-23-3 CAPLUS  
 CN 2-Thiophenecarboxamide, 5-[5-(2-amino-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929040-27-7 CAPLUS  
 CN 2-Thiophenecarboxamide, 5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-29-9 CAPLUS  
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-[(1-methyl-4-piperidinyl)amino]-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.


RN 929040-39-1 CAPLUS  
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-[3-(4-ethyl-1-piperazinyl)propyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929040-42-6 CAPLUS  
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-17-0 CAPLUS  
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


189 of 356



RN 929095-18-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-19-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-20-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


190 of 356



RN 929095-21-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-22-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(1-methyl-4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-23-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyloxy)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


191 of 356



RN 929095-40-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-45-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylthio)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-64-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


192 of 356



RN 929276-39-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(6-fluoro-3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-40-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(6-chloro-3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929276-41-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-42-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-43-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-45-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-46-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-49-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-ethyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-50-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1R)-3-piperidinylmethoxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-51-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(2R)-2-morpholinylmethoxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-53-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-cyclopentyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-55-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[7-bromo-6-(4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929276-58-4 CAPLUS

CN Formic acid, compd. with 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5,7-dibromo-6-(4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-2-thiophenecarboxamide (1:1)

10522958-updated

197 of 356


(CA INDEX NAME)

CM 1

CRN 929276-57-3

CMF C25 H23 Br2 Cl N4 O3 S

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

Ome: CH-OH

RN 929276-60-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyl)oxy]-5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929276-62-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[3-

10522958-updated

199 of 356


benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 929276-68-6

CMF C27 H27 F3 N4 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 929276-72-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(1R)-1-(2-chlorophenyl)ethoxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 929276-71-1

CMF C27 H27 F3 N4 O3 S


Absolute stereochemistry.

10522958-updated

198 of 356

(dimethylamino)propoxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-64-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(methylsulfonyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-66-4 CAPLUS

CN Sulfamic acid, N,N-dimethyl-, 1-[5-[aminocarbonyl]-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929276-69-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(1R)-1-(2-chlorophenyl)ethoxy]-1H-

10522958-updated

200 of 356



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 929276-74-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(cis-4-aminocyclohexyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-76-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-piperidinylsulfonyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-77-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[3-(dimethylamino)propyl]sulfonyl]methyl]-1H-benzimidazol-1-yl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-78-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[3-(dimethylamino)propyl]sulfonyl]methyl]-1H-benzimidazol-1-yl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-79-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[[[3-(dimethylamino)propyl]sulfonyl]methyl]-1H-benzimidazol-1-yl]]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-84-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[4-(piperidinyl)sulfonyl]methyl]-1H-benzimidazol-1-yl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-85-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(2-amino-2-iminoethyl)-1H-benzimidazol-1-yl]]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-87-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[4-(piperidinyl)ethenyl]-1H-benzimidazol-1-yl]]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1



RN 929276-80-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[[[3-(dimethylamino)propyl]sulfonyl]methyl]-1H-benzimidazol-1-yl]]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-82-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[3-(dimethylamino)propyl]sulfonyl]methyl]-1H-benzimidazol-1-yl]]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929276-83-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[[[3-(dimethylamino)propyl]sulfonyl]methyl]-1H-benzimidazol-1-yl]]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

CRN 929276-86-8  
CMP C27 H27 Cl N4 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMP C2 H F3 O2


RN 929276-89-1 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[4-(piperidinyl)carbonyl]-1H-benzimidazol-1-yl]]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 929276-88-0  
CMP C26 H25 Cl N4 O3 S

Absolute stereochemistry.







CM 2

CRN 76-05-1  
CMF C2 H F3 O2RN 929276-92-6 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(difluoro(1-methyl-4-piperidyl)methyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 929276-94-8 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-96-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(4-amino-1-piperidyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 929276-97-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 929276-98-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[4-(ethylsulfonyl)-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.

RN 929276-99-3 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-[[1-(dimethylamino)ethyl]-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.

RN 929277-00-9 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-[2-(dimethylamino)ethyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 929277-02-1 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[2-(1-piperazinyl)-4-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A

RN 929277-04-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[1,2-dihydro-2-oxo-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-05-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[2-(1-piperazinyl)-4-pyrimidinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 929277-06-5 CAPLUS

RN 929277-12-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-[2-[(methylsulfonyl)ethyl]amino]ethyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-15-6 CAPLUS

CN 2-Propanesulfonic acid, 1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 929277-18-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(phenylsulfonyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




CN 2-Thiophenecarboxamide, 3-[(2-chloro-3-pyridinyl)methoxy]-5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)



RN 929277-07-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[3-amino-2-chlorophenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-08-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-hydroxyphenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-21-4 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-, 1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-24-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-[(methylsulfonyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-26-9 CAPLUS


CN Ethanesulfonic acid, 1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929277-27-0 CAPLUS  
 CN 1-Propanesulfonic acid, 1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-28-1 CAPLUS  
 CN Formic acid, compd. with 1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl N-[3-(dimethylamino)propyl]-N-methylsulfamate (1:1) (CA INDEX NAME)

CM 1

CRN 929277-28-1  
 CMF C27 H30 F3 N5 O5 S2

Absolute stereochemistry.



CM 2

CRN 64-10-6  
 CMF C H2 O2


OH = CH-OH

RN 929277-32-7 CAPLUS  
 CN 2-Thiophenecarboxamide, 5-[6-[difluoro(4-piperidynylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 929277-31-6  
 CMF C27 H25 F5 N4 O4 S2

Absolute stereochemistry.




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 929277-34-9 CAPLUS  
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidynyl)carbonyl]-1H-benzimidazol-1-yl]-, (CA INDEX NAME)

Absolute stereochemistry.



RN 929277-36-1 CAPLUS  
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-[difluoro(1-methylethyl)-4-piperidynyl)methyl]-1H-benzimidazol-1-yl]-, (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-40-7 CAPLUS  
 CN β-Alanine, N-[[1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 929277-39-4  
 CMF C24 H23 Cl N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 929277-43-0 CAPLUS  
 CN L-Alanine, N-[[3-[1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]propyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 929277-42-9  
 CMF C26 H27 Cl N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 929277-45-2 CAPLUS  
 CN L-Valine, N-[[3-[1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]propyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 929277-44-1  
 CMF C28 H31 Cl N4 O4 S

Absolute stereochemistry.




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 929277-47-4 CAPLUS  
CN L-Alanine, N-[(1-{5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl}-1H-benzimidazol-6-yl)methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
CRN 929277-46-3  
CMF C24 H23 Cl N4 O4 S

Absolute stereochemistry.



CM 2  
CRN 76-05-1


CMF C2 H F3 O2



RN 929277-50-9 CAPLUS  
CN L-Alanine, N-[2-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
CRN 929277-49-6  
CMF C25 H25 Cl N4 O4 S

Absolute stereochemistry.




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 929277-52-1 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[2-(methylsulfonyl)ethyl]amino]methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-55-4 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[6-[[[2-(methylsulfonyl)ethyl]amino]methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1  
CRN 929277-54-3  
CMF C23 H24 Cl N5 O2 S

Absolute stereochemistry.




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 929277-61-2 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[2-(dimethylamino)ethyl]methylamino]methyl]-1H-benzimidazol-1-yl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1  
CRN 929277-60-1  
CMF C26 H30 Cl N5 O2 S

Absolute stereochemistry.




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2




RN 929277-64-5 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[1-(2-hydroxyethyl)-4-piperidyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929277-67-8 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[1-(2-(methylsulfonyl)ethyl)-4-piperidyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-71-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-72-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(2-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-73-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

RN 929277-78-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(1H-pyrrol-2-yl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-79-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(2-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-81-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(6-amino-3-pyridazinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



RN 929277-74-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(5-(4-pyridinyl)-1H-benzimidazol-1-yl)- (CA INDEX NAME)



Absolute stereochemistry.



RN 929277-76-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(5-phenyl-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-83-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(3,5-dimethyl-4-isoxazolyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-85-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-(6-chloro-5-hydroxy-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-86-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(6-amino-2-methyl-3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)


10522958-updated 225 of 356  
benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-87-2 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(1-methyl-1H-imidazol-5-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-88-3 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[5-(2-amino-5-pyrimidinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




10522958-updated 227 of 356




RN 929277-96-3 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[4-(dimethylamino)-1-piperidinyl]methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929277-99-5 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[6-[(aminosulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929278-00-2 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[5-(3-amino-4-methoxyphenyl)-1H-benzimidazol-1-yl]-

10522958-updated 226 of 356


RN 929277-90-7 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[5-[2-(dimethylamino)-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929277-92-9 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[5-[2-(methylamino)-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-94-1 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[5-(2-methyl-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.


10522958-updated 228 of 356  
yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929278-02-4 CAPLUS  
CN Benzenepropanoic acid, 3-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929278-04-6 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-(methylamino)-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


229 of 356



RN 929278-06-8 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(6-methoxy-3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-08-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(6-amino-3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-10-4 CAPLUS

10522958-updated


231 of 356



RN 929278-16-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(6-(1-methyl-4-piperidinyl)ethoxy)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-24-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(trans-4-aminocyclohexyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929278-25-1 CAPLUS


CN 2-Thiophenecarboxamide, 5-[6-(cis-4-aminocyclohexyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

10522958-updated

230 of 356

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(6-(4-methyl-1-piperazinyl)-3-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-12-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(6-(4-amino-1-piperidinyl)-3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929278-14-8 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(6-(methyl(1-methyl-4-piperidinyl)amino)-3-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated

232 of 356


Absolute stereochemistry.



RN 929278-27-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(6-(trans-4-(dimethylamino)cyclohexyl)-1H-benzimidazol-1-yl)-1-methyl-3-piperidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-29-5 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(6-(trans-4-(dimethylamino)cyclohexyl)-1H-benzimidazol-1-yl)-1-methyl-3-piperidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-34-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(6-(trans-4-(dimethylamino)cyclohexyl)-1H-benzimidazol-1-yl)-1-methyl-3-piperidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 5 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN

AN 2007:283577 CAPLUS [Full-text](#)

DN 146:337898

TI Preparation of benzimidazolyl thiophene derivatives as PLK modulators

IN Cheung, Mui; Badiang, Jennifer Gabriel; Donaldson, Kelly Horne; Rheault, Tara Renae

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 80pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO. (NO US CASE-NOT ODP)	DATE
NO 2007030359	A1	20070315	NO 2006-US33616	20060828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2005-714303P	P	20050906	(NOT PRIOR ART)	

GI




AB The present invention provides 5-heteroaryl substituted benzimidazole thiophene derivs., pharmaceutical compns. containing the same, processes for preparing the same and their use as pharmaceutical agents. For example, 1 was provided in a multi-step synthesis starting from the reaction of Me 3-hydroxy-5-nitro-2-thiophenecarboxylate with (1S)-1-[(2-(trifluoromethyl)phenyl)ethoxy]-2-thiophenecarboxamide. The prepared title compds. were tested for inhibition of PLK-1 (polo-like kinase 1), methylene blue cell growth inhibition, cell-titer glo cell growth inhibition and pharmacokinetics.

IT 660869-61-4P 660869-62-5P 660869-69-2P 660869-67-2P 929040-02-9P, 5-[5-[6-(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]-3-[[[(1R)-1-[(2-(trifluoromethyl)phenyl)ethoxy]-2-thiophenecarboxamide 929040-15-4P, 5-[5-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[[[(1R)-1-[(2-(trifluoromethyl)phenyl)ethoxy]-2-thiophenecarboxamide 929040-22-2P, 5-[5-[2-[(1-methyl-4-piperidinyl)amino]-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[[[(1R)-1-[(2-(trifluoromethyl)phenyl)ethoxy]-2-thiophenecarboxamide 929040-25-3P, 5-[5-[2-Amino-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[[[(1R)-1-[(2-(trifluoromethyl)phenyl)ethoxy]-2-thiophenecarboxamide 929040-27-7P, 5-[5-[1H-Pyrazol-4-yl]-1H-benzimidazol-1-yl]-3-[[[(1R)-1-[(2-(trifluoromethyl)phenyl)ethoxy]-2-thiophenecarboxamide 929040-29-9P, 3-[[[(1R)-1-[(2-chlorophenyl)ethoxy]-5-[5-[6-[(1-methyl-4-piperidinyl)amino]-3-pyridinyl]-1H-benzimidazol-1-yl]-2-thiophenecarboxamide 929040-35-3P 929040-39-1P, 3-[[[(1R)-1-[(2-chlorophenyl)ethoxy]-5-[5-[1-[3-(4-ethyl-1-piperazinyl)propyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-2-thiophenecarboxamide 929040-42-6P, 3-[[[(1R)-1-[(2-chlorophenyl)ethoxy]-5-[5-[1-methyl-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-2-thiophenecarboxamide (Preparation of benzimidazolyl thiophene deriva. as Polo-like kinases (PLK) modulators)


RN 660869-61-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[1-(2-chlorophenyl)ethoxy]-5-[5,6-dimethoxy-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 660869-62-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5,6-dimethoxy-1H-benzimidazol-1-yl]-3-[1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)




RN 660869-69-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-methoxy-5-[3-(2-oxo-1-pyrrolidinyl)propoxy]-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)



RN 660869-93-2 CAPLUS


CN 1H-Benzimidazole-5-carboxamide, 1-[5-(aminocarbonyl)-4-[[2-(trifluoromethyl)phenyl]methoxy]-2-thienyl]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)



RN 929040-03-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[6-(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]-3-[[[(1R)-1-[(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-16-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[[[(1R)-1-[(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A





PAGE 2-A




RN 929040-22-2 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[5-[2-[(1-methyl-4-piperidinyl)amino]-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-36-8 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-[(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-39-1 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-[3-(4-ethyl-1-piperazinyl)propyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-23-3 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[5-(2-amino-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-27-7 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-29-9 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-[(1-methyl-4-piperidinyl)amino]-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929040-42-6 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



IT 929040-41-7P 929040-44-8P 929040-45-9P  
929040-46-0P 929040-47-1P 929040-48-2P  
929040-49-3F 929040-50-CP 929040-51-7P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of benzimidazolyl thiophene derivs. as Polo-like kinases (PLK) modulators)

RN 929040-43-7 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[5-[6-[(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-44-8 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[5-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-

benzimidazol-1-yl]-3-[(1S)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A

RN 929040-45-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[2-[(1-methyl-4-piperidinyl)amino]-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1S)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-46-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(2-amino-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1S)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-47-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-[(1S)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-48-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-[(1-methyl-4-piperidinyl)amino]-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-49-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-[(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-50-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-[3-(4-ethyl-1-piperazinyl)propyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-51-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-methyl-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 929040-05-EP, Methyl 5-(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethyl]oxy]thiophene-2-carboxylate

929040-11-6P 929040-14-2P 929040-18-6P, 5-(5-Bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethyl]oxy]thiophene-2-carboxamide 929040-21-1P, 5-[5-(2-Fluoro-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethyl]oxy]-2-thiophenecarboxamide 929040-24-4P, Methyl 5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethyl]oxy]-2-thiophenecarboxylate 929040-25-5P, Methyl 5-[5-[2-[(diphenylmethylidene)amino]-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethyl]oxy]-2-thiophenecarboxylate


Chemical structure: COc1cc(C(=O)OC)sc(NC2=CC=CC=C2)c1N3C=NC2=CC=CC=C2  
 1,1-Dimethylethyl 4-[5-(1-{[2-(trifluoromethyl)phenyl]ethoxy}-1H-benzimidazol-5-yl)-2-pyridinyl]-1-piperazinecarboxylate 929040-40-4f  
 929040-41-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of benzimidazolyl thiophene derivs. as Polo-like kinases (PLK) modulators)

RN 929040-09-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-bromo-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-11-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-14-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-18-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-bromo-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-21-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(2-fluoro-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-24-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-25-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[2-[(diphenylmethylene)amino]-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-26-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(2-amino-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-28-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-32-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RH 929040-33-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-34-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(6-fluoro-3-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-40-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(6-fluoro-3-pyridinyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-41-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-(3-ethyl-1-piperazinyl)propyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-37-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-38-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 6 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:282094 CAPLUS Full-text

DN 146:337890

TI Preparation of thiophenyl benzimidazole derivatives for treatment of conditions mediated by polo-like kinases

IN Cheung, Mui; Emmette, Kyle Allen; Salovich, James Michael

PA Smithkline Beecham Corp., USA

SO PCT Int. Appl., 107pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007030361	A2	20070315	WO 2006-US33683	20060828
WO 2007030361	A3	20070531		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GN, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RN: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BM, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, CA


US 2007270437 A1 20071122 US 2006-467577 20060828

(CHECKED DOC - NOT ODP FOR INSTANT ELECTED)

PRAI US 2005-714337P P 20050906 (NOT PRIOR ART)

US 2006-786244P P 20060327

GI



1

AB Eight thiophenyl benzimidazole derivs. and pharmaceutically acceptable salts and solvates thereof were prepared for the treatment of conditions mediated by polo-like kinases (PLK). For example, N-methylpiperazine was treated with Me 5-[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethyl]oxy]thiophene-2-carboxylate (preparation given) at 60 °C for 18 h in dioxane to give an intermediate which was further reacted with ammonia in MeOH at 80 °C for 40 h in a sealed flask to give 1 as a final product. 1 showed superior enzyme and cell potency in PLK1 enzyme assay and methylene blue cell proliferation assay in multiple cell lines. I also had superior protein binding in human serum by equilibrium dialysis assay. On the other hand, 1 showed good solubility in 0.05 M pH 7.4 phosphate buffer.

IT 103405-16-9P 929095-17-0F 929095-18-1P  
929095-19-2P 929095-20-5P 929095-21-6P  
929095-22-7F 929095-23-8F 929095-24-1P  
929095-25-2P 929095-26-3P 929095-27-4P  
929095-28-5P 929095-29-6P 929095-30-7P  
929095-31-8F 929095-32-9P  
929095-33-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of thiophenyl benzimidazole derivs. for treatment of conditions mediated by polo-like kinases)

RN 929095-16-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-17-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-18-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-19-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-20-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-21-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-(4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-22-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-23-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-26-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-27-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-28-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


257 of 356



RN 929095-29-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(1S)-1-(2-chlorophenyl)ethoxy]-1H-benzimidazol-1-yl]-3-[(1S)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-30-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-31-8 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-3-[(1S)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


258 of 356



RN 929095-32-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-33-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 660869-55-7 660869-61-4 660869-62-5

660869-71-6 660869-79-4


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of thiophenyl benzimidazole derivs. for treatment of conditions mediated by polo-like kinases)

10522958-updated

259 of 356


RN 660869-56-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(methylsulfonyl)-1H-benzimidazol-1-yl]-3-[(2-(trifluoromethyl)phenyl)methoxy]- (CA INDEX NAME)




RN 660869-61-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[1-(2-chlorophenyl)ethoxy]-5-[5,6-dimethoxy-1H-benzimidazol-1-yl]- (CA INDEX NAME)



RN 660869-62-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5,6-dimethoxy-1H-benzimidazol-1-yl]-3-[1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)




RN 660869-71-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-methoxy-6-[2-(4-methyl-1-piperazinyl)ethoxy]-1H-benzimidazol-1-yl]-3-[(2-(trifluoromethyl)phenyl)methoxy]- (CA INDEX NAME)


10522958-updated

260 of 356



RN 660869-79-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(4-piperidinylmethoxy)-1H-benzimidazol-1-yl]-3-[(2-(trifluoromethyl)phenyl)methoxy]- (CA INDEX NAME)



IT 440876-07-5P 929095-36-5P 929095-29-6P

929095-40-3P 929095-41-3P 929095-42-1P

929095-43-2P 929095-44-3P 929095-45-4P

929095-46-5P 929095-47-6P 929095-48-7P

929095-49-8P 929095-50-1P 929095-51-2P

929095-52-3P 929095-53-4P 929095-54-5P

929095-55-6P 929095-56-7P 929095-57-8P

929095-58-9P 929095-59-0P 929095-60-1P

929095-61-2P 929095-62-3P 929095-63-4P

929095-64-5P 929095-65-6P 929095-66-7P

929095-67-8P 929095-68-9P 929095-69-0P


929095-70-1P 929095-71-2P 929095-72-3P

929095-73-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of thiophenyl benzimidazole derivs. for treatment of conditions mediated by polo-like kinases)


RN 660870-07-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-bromo-1H-benzimidazol-1-yl]-3-hydroxy-, methyl ester (CA INDEX NAME)




RN 929095-38-5 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-((2,2-dimethyl-1-oxopropoxy)methyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-39-6 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-(hydroxymethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-40-9 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-44-3 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-((methylthio)methyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-45-4 CAPLUS  
CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-((methylthio)methyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-46-5 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-(bromo-1H-benzimidazol-1-yl)-3-[(1,1-dimethyl-2-oxo-2-(dimethylamino)ethyl)oxy]-, methyl ester (CA INDEX NAME)




RN 929095-41-0 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-((methylthio)methyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-42-1 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[6-((methylthio)methyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-43-2 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-((methylsulfonyl)methyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-47-6 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-(bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929095-48-7 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-(6-ethenyl-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-49-8 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[6-(1,2-dihydroxyethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


265 of 356



RN 929095-50-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(6-formyl-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-51-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-54-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(methoxymethoxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


267 of 356



RN 929095-62-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(2,2-dimethyl-1-oxopropoxy)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-63-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(hydroxymethyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-64-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


266 of 356



RN 929095-55-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(6-hydroxy-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-56-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-5-[6-[(trifluoromethyl)sulfonyloxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-59-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(dimethoxymethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


268 of 356



RN 929095-66-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-67-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(6-hydroxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-71-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-methoxyphenyl)methoxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.






RN 929095-74-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-75-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-76-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-

RN 929095-79-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyloxy)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



X L6 ANSWER 7 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:181791 CAPLUS [Full-text](#)

DN 146:414432

TI In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1

AU Lansing, Timothy J.; McConnell, Randy T.; Duckett, Derek R.; Spehar, Glenn M.; Knick, Victoria B.; Hassler, Daniel F.; Moro, Nobuhiro; Furuta, Masaaki; Emmitt, Kyle A.; Gilmer, Tona M.; Mook, Robert A., Jr.; Cheung, Mui

CS Oncology Biology, GlaxoSmithKline, Research Triangle Park, NC, USA

SO [Molecular Cancer Therapeutics](#) (2007), 6(2), 450-459 [NOT PRIOR ART/ODP]

CODEN: MCTOCF; ISSN: 1535-7163

PB American Association for Cancer Research


DT Journal

LA English

AB Polo-like kinase 1 (PLK1) plays key roles in the regulation of mitotic progression, including mitotic entry, spindle formation, chromosome segregation, and cytokinesis. PLK1 expression and activity are strongly linked to proliferating cells. Many studies have shown that PLK1 expression is elevated in a variety of tumors, and high expression often correlates with poor prognosis. Using a variety of methods, including small-mol. inhibition of PLK1 function and/or activity, apoptosis in cancer cell lines, cell cycle arrest in normal cell lines, and antitumor activity in vivo have been observed. In the present study, the authors have examined the in vitro biol. activity of a novel and selective thiophene benzimidazole ATP-competitive inhibitor of PLK1 and PLK3 (5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)benzyl]oxy]thiophene-2-carboxamide, called compound 1). Compound 1 has low nanomolar activity against the PLK1 and PLK3 enzymes and potentially inhibits the proliferation of a wide variety of tumor cell lines. In the lung adenocarcinoma cell line NCI-H460, compound 1 induces a transient G2-M arrest, mitotic spindle defects, and a multinucleate phenotype resulting in apoptosis, whereas normal human diploid fibroblasts arrest in G2-M and show little apoptosis. The authors also describe a cellular mechanistic assay that was developed to identify potent intracellular inhibitors of PLK1. In addition to its potential as a therapeutic agent for treating cancer, compound 1 is also a useful tool mol. for further investigation of the biol. functions of PLK1 and PLK3.

(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-77-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-78-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(1-methyl-4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




IT 660868-91-7

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(in vitro biol. activity of a small-mol. inhibitor of polo-like kinase 1)

RN 660868-91-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)



RE.CHT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 8 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:1190032 CAPLUS [Full-text](#)

DN 146:54723

TI 5-[(1H-Benzimidazol-1-yl)-3-alkoxy-2-thiophenecarbonitriles as potent, selective, inhibitors of IKK- $\alpha$  kinase

AU Bamborough, Paul; Christopher, John A.; Cutler, Geoffrey J.; Dickson, Marion C.; Mellor, Geoffrey W.; Morey, James V.; Patel, Champa B.; Shewchuk, Lisa M.

CS Medicines Research Centre, GlaxoSmithKline R &amp; D, Hertfordshire, SG1 2NY, UK

SO [Bioorganic & Medicinal Chemistry Letters](#) (2006), 16(24), 6236-6240

CODEN: BMCLEs; ISSN: 0960-894X [NOT PRIOR ART/NOT ODP]


PB Elsevier Ltd.

DT Journal

LA English

OS CASREACT 146:54723

GI




AB The identification and hit-to-lead exploration of a novel, potent and selective series of substituted benzimidazole-thiophene carbonitrile inhibitors of IKK- $\epsilon$  kinase is described. Compound 12e (I) was identified with an IKK- $\epsilon$  enzyme potency of pIC<sub>50</sub> 7.4, and has a highly encouraging wider selectivity profile, including selectivity within the IKK kinase family.

IT 916985-24-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(benzimidazolyl alkoxy thiophenecarbonitriles as inhibitors of IKK- $\epsilon$  kinase)

RN 916985-24-5 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-hydroxy- (CA INDEX NAME)



IT 960862-30-5P 862812-86-6P 862812-89-3P

862812-94-0P 862812-98-4P 862813-04-5P

942613-10-5P 862813-17-0P 916985-36-5P


916985-39-2P 916985-41-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(benzimidazolyl alkoxy thiophenecarbonitriles as inhibitors of IKK- $\epsilon$  kinase)


RN 960862-30-5 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 862812-86-0 CAPLUS

CN 2-Thiophenecarbonitrile, 3-[[1R]-1-[(2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)



RN 862813-04-5 CAPLUS


CN 2-Thiophenecarbonitrile, 5-[5-(3-hydroxypropoxy)-6-methoxy-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)



RN 862813-12-5 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[1R]-1-[[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862813-17-0 CAPLUS


CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862812-89-3 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(1H-benzimidazol-1-yl)-3-(phenylmethoxy)- (CA INDEX NAME)




RN 862812-94-0 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[6-methoxy-5-[2-(4-morpholinyl)ethoxy]-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 862812-98-4 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[2-(methylsulfonyl)phenyl]methoxy]- (CA INDEX NAME)




RN 916985-36-9 CAPLUS

CN 2-Thiophenecarbonitrile, 3-(cyclopropylmethoxy)-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)




RN 916985-39-2 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 916985-41-6 CAPLUS


CN Benzamide, 4-[[[2-cyano-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-thienyl]oxy]methyl]- (CA INDEX NAME)




IT 660868-39-3 CAPLUS  
 660868-39-3 662613-38-5 916985-51-2  
 916985-51-2  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (benzimidazolyl) alkoxy thiophenecarbonitriles as inhibitors of IKK- $\epsilon$  kinase  
 RN 660868-39-3 CAPLUS  
 CN 2-Thiophenecarboxamide, 5-(1H-benzimidazol-1-yl)-3-[(4-methylphenyl)methoxy]- (CA INDEX NAME)




RN 660870-60-0 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-3-(phenylmethoxy)- (CA INDEX NAME)




RN 862813-19-2 CAPLUS



RN 916985-22-3 CAPLUS  
 CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(4-methylsulfonyl)phenyl]methoxy)- (CA INDEX NAME)




IT 916985-25-6 CAPLUS  
 916985-25-6 916985-25-6 916985-25-6  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (benzimidazolyl) alkoxy thiophenecarbonitriles as inhibitors of IKK- $\epsilon$  kinase  
 RN 916985-25-6 CAPLUS  
 CN 2-Thiophenecarbonitrile, 3-hydroxy-5-[6-methoxy-5-[2-(4-morpholinyl)ethoxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 916985-26-7 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(tetrahydro-2-furanyl)methoxy]- (CA INDEX NAME)




RN 862813-28-3 CAPLUS  
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 862813-38-5 CAPLUS  
 CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(tetrahydro-2-furanyl)methoxy]- (CA INDEX NAME)




RN 916985-21-2 CAPLUS  
 CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(4-methylsulfonyl)phenyl]methoxy)- (CA INDEX NAME)

CN 2-Thiophenecarbonitrile, 3-hydroxy-5-[5-(3-hydroxypropoxy)-6-methoxy-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 916985-27-8 CAPLUS  
 CN 2-Thiophenecarbonitrile, 5-(1H-benzimidazol-1-yl)-3-hydroxy- (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 9 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN  
 AN 2006:1190017 CAPLUS Full-text  
 DN 146:74597  
 TI Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists  
 AU Bell, Ian M.; Bednar, Rodney A.; Fay, John P.; Gallicchio, Steven N.; Hochman, Jerome H.; McMasters, Daniel R.; Miller-Stein, Cynthia; Moore, Eric L.; Mosser, Scott D.; Pudvah, Nicole T.; Quigley, Amy G.; Salvatore, Christopher A.; Stump, Craig A.; Theberge, Cory R.; Wong, Bradley K.; Zartman, C. Blair; Zhang, Xu-Fang; Kane, Stefanie A.; Graham, Samuel L.; Vacca, Joseph P.; Williams, Theresa M.  
 CS Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA, 19486, USA  
 SO Bioorganic & Medicinal Chemistry Letters (2006), 16(24), 6165-6169 [NOT PRIOR ART/ODP]  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 146:74597  
 GI



AB A rapid analog approach to identification of spirohydanotin-based CGRP antagonists provided novel, low mol. weight leads. Modification of these leads afforded a series of nanomolar benzimidazolinone-based CGRP receptor antagonists. The oral bioavailability of these antagonists was inversely correlated with polar surface area, suggesting that membrane permeability was a key limitation to absorption. Optimization provided compound 12 (I), a potent CGRP receptor antagonist ( $K_i = 21$  nM) with good oral bioavailability in three species.


IT 916919-57-5

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (orally bioavailable spirohydanotin CGRP receptor antagonists)

RH 916919-57-5 CAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[(2'R)-1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl]-2,3-dihydro-2-oxo-3-(tetrahydro-1,1-dioxido-3-thienyl)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 10 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN

AN 2006:1172142 CAPLUS [Full-text](#)

DN 146:55726

TI Bayesian-regularized genetic neural networks applied to the modeling of

non-peptide antagonists for the human luteinizing hormone-releasing hormone receptor

AU Fernandez, Michael; Caballero, Julio

CS Molecular Modeling Group, Center for Biotechnological Studies, University of Matanzas, Matanzas, 44740, Cuba

SO *Journal of Molecular Graphics & Modelling* (2006), 25(4), 410-422

CODEN: JMGMP1; ISSN: 1093-3263 [NOT PRIOR ART/ODP]

PB Elsevier Inc.

DT Journal

LA English

AB Bayesian-regularized genetic neural networks (BRGNNs) were used to model the binding affinity (IC50) for 128 non-peptide antagonists for the human LH-releasing hormone (LHRH) receptor using 2D spatial autocorrelation vectors. As a preliminary step, a linear dependence was established by multiple linear regression (MLR) approach, selecting the relevant descriptors by genetic algorithm (GA) feature selection. The linear model showed to fit the training set ( $N = 102$ ) with  $R^2 = 0.746$ , meanwhile BRGNN exhibited a higher value of  $R^2 = 0.871$ . Beyond the improvement of training set fitting, the BRGNN model overcame the linear one by being able to describe 85% of test set ( $N = 26$ ) variance in comparison with 73% the MLR model. The authors' non-linear QSAR model illustrates the importance of an adequate distribution of atomic properties represented in topol. frames and reveals the electronegativities, masses and polarizabilities as the most influencing atomic properties in the structures of the heterocycles under anal. for having an appropriate LHRH antagonistic activity. Furthermore, the ability of the non-linear selected variables for differentiating the data was evidenced when total data set was well distributed in a Kohonen self-organizing map (SOM).


IT 917017-69-7

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(Bayesian-regularized genetic neural networks applied to modeling binding affinity for non-peptide antagonists for human LH-RH receptor using 2D spatial autocorrelation vectors)

RH 917017-69-7 CAPLUS

CN 1H-Benzimidazole-5-sulfonamide, 2-ethoxy-N-[(4-fluorophenyl)methyl]-1-(3-thienyl)- (CA INDEX NAME)



RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2008 ACS ON STN

AN 2006:971442 CAPLUS [Full-text](#)

DN 145:505375

TI 2-Aminopyrimidine-4,6-diol as an efficient ligand for solvent-free copper-catalyzed N-arylations of imidazoles with aryl and heteroaryl halides

AU Xie, Ye-Xiang; Pi, Shao-Feng; Wang, Jian; Yin, Du-Lin; Li, Jin-Heng

CS Key Laboratory of Chemical Biology & Traditional Chinese Medicine Research (Ministry of Education), College of Chemistry and Chemical Engineering, Hunan Normal University, Changsha, 410081, Peop. Rep. China

SO *Journal of Organic Chemistry* (2006), 71(21), 8324-8327

CODEN: JOCEAH; ISSN: 0022-3263 [NOT PRIOR ART/ODP]

PB American Chemical Society

DT Journal

LA English

OS CASREACT 145:505375

AB Solvent-free copper-catalyzed N-arylations of imidazoles with aryl and heteroaryl halides have been demonstrated. In the presence of CuBr, 2-aminopyrimidine-4,6-diol, and TBAF (n-Bu4NF), a variety of imidazoles underwent the N-arylation reaction with aryl and heteroaryl halides smoothly in moderate to excellent yields. Noteworthy is that the reaction was conducted under solvent-free conditions.


IT 884068-82-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of N-arylimidazoles and N-arylbenzimidazoles via copper-aminopyrimidinol-catalyzed N-arylation with imidazoles or benzimidazoles with aryl halides under solvent-free conditions)

RH 884068-82-0 CAPLUS

CN 1H-Benzimidazole, 1-(2-thienyl)- (CA INDEX NAME)



RE.CNT 81 THERE ARE 81 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 12 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN

AN 2006:398159 CAPLUS [Full-text](#)

DN 145:83268

TI Cui catalyzed C-N bond forming reactions between aryl/heteroaryl bromides and imidazoles and imidazoles [Bmin]BF4

AU Lv, Xin; Wang, Zhiming; Bao, Weiliang

CS Zhejiang University, Department of Chemistry, Zhejiang, 310028, Peop. Rep. China

SO *Tetrahedron* (2006), 62(20), 4756-4761

CODEN: TETRAH; ISSN: 0040-4020 [NOT PRIOR ART/ODP]

PB Elsevier B.V.

DT Journal

LA English

OS CASREACT 145:83268

AB By using CuI as the catalyst and L-Proline as the ligand, the Ullmann-type coupling reactions of aryl/heteroaryl bromides and imidazoles in [Bmin]BF4 at 105-115 °C gave the corresponding N-arylimidazoles/N- heteroarylimidazoles in good yields. The system offers a convenient, recyclable, and environmentally benign method for these coupling reactions.


IT 312559-35-6P 884068-82-0P 892423-38-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(copper catalyzed Ullmann-type coupling reaction of aryl/heteroaryl bromides and imidazoles in ionic liq.)


RH 312559-35-6 CAPLUS

CN 1H-Benzimidazole, 1-(3-thienyl)- (CA INDEX NAME)




RH 884068-82-0 CAPLUS

CN 1H-Benzimidazole, 1-(2-thienyl)- (CA INDEX NAME)



RH 892483-38-4 CAPLUS

CN 1H-Benzimidazole, 1-(5-methyl-2-thienyl)- (CA INDEX NAME)



RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 13 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN

AN 2005:823697 CAPLUS [Full-text](#)

DN 143:32853

TI Preparation of benzimidazolyl substituted thiophene derivatives with activity against IKK3

IN Bamborough, Paul; Morey, James Vaughan

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005075465	A1	20050818	WO 2005-EP1432	20050207
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MY, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GO, GW, ML, MR, NE, SN, TD, TG			
EP 1720864	A1	20061115	EP 2005-707356	20050207

285 of 356

Chemical structures of polymers 1 and 11 are shown. Polymer 1 is a poly(2,6-pyridine diene) with a side chain containing a 2-cyano-5-hydroxythiophen-3-yl group. Polymer 11 is a poly(2,6-pyridine diene) with a side chain containing a 2-cyano-5-(4-hydroxyphenyloxy)thiophen-3-yl group.

IT	602094-54-2P	602095-32-3P	602012-84-8P
	602013-74-0P	602013-84-2P	602013-92-3P
	602013-94-0P	602013-96-2P	602013-98-3P
	602013-00-1P	602013-02-3P	602013-04-5P
	602013-06-7P	602013-08-6P	602013-10-1P
	602013-12-5P	602013-14-7P	602013-16-5P
	602013-18-5P	602013-20-1P	602013-22-1P
	602013-24-0P	602013-26-5P	602013-28-5P
	602013-30-0P	602013-32-5P	602013-34-5P
	602013-36-0P	602013-38-5P	602013-40-5P
	602013-42-0P	602013-44-5P	602013-46-5P
	602013-48-0P	602013-50-5P	602013-52-5P
	602013-54-0P	602013-56-5P	602013-58-5P
	602013-60-0P	602013-62-5P	602013-64-5P
	602013-66-0P	602013-68-5P	602013-70-5P
	602013-72-0P	602013-74-5P	602013-76-5P
	602013-78-0P	602013-80-5P	602013-82-5P
	602013-84-0P	602013-86-5P	602013-88-5P
	602013-90-0P	602013-92-5P	602013-94-5P
	602013-96-0P	602013-98-5P	602013-00-5P

```

(uses)
  (preparation of benzimidazolyl substituted thiophene derivs. with activity
  against IKK3)


```

CN 2-Thiophenecarbonitrile, 5-(1H-benzimidazol-1-yl)-3-[(2-


287 of 356

COC1=CC=C2C(=C1)N=CN=C2C3=CC(=C(C=C3)C#N)OC(=O)C4=CC=C(C=C4)Cl


2-Thiophenecarbonitrile, 5-(1H-benzimidazol-1-yl)-3-(phenylmethoxy)- (CA  
INDEX NAME)



2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(1-methyl-1H-benzotriazol-6-yl)methoxy]- (CA INDEX NAME)




2-Thiophenecarbonitrile, 5-{6-methoxy-5-[2-(4-morpholinyl)ethoxy]-1H-benzimidazol-1-yl}-3-{[2-(trifluoromethyl)phenyl]methoxy}- (CA INDEX NAME)




286 of 356

Cc1ccccc1COc2cc(C#N)sc2Nc3c[nH]c4ccccc34

2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethyl)phenyl)methoxy]- (CA INDEX NAME)




2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(4-(hydroxymethyl)phenyl)methoxy]- (CA INDEX NAME)




2-Thiophenecarbonitrile, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)

288 of 356


2-Thiophenecarbonitrile, 3-[(2,5-difluorophenyl)methoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)




2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-methylsulfonyl)phenyl]methoxy]- (CA INDEX NAME)




CN 2-Thiophenecarbonitrile, 5-(5-chloro-1H-benzimidazol-1-yl)-3-(phenylmethoxy)- (CA INDEX NAME)




CN 2-Thiophenecarbonitrile, 3-((2,6-difluorophenyl)methoxy)-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)




RN 862813-04-5 CAPLUS  
CN 2-Thiophenecarbonitrile, 5-[(3-hydroxypropoxy)-6-methoxy-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 862813-06-7 CAPLUS  
CN 2-Thiophenecarbonitrile, 3-[(3-bromo-4-pyridinyl)methoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)




RN 862813-08-9 CAPLUS  
CN 2-Thiophenecarbonitrile, 3-(cyclohexylmethoxy)-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)




RN 862813-15-8 CAPLUS  
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[2-(trifluoromethoxy)phenyl]methoxy]- (CA INDEX NAME)




RN 862813-16-9 CAPLUS  
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[2-methoxyphenyl]methoxy]- (CA INDEX NAME)



RN 862813-17-0 CAPLUS  
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 862813-10-3 CAPLUS  
CN 1H-Benzimidazole-5-carboxamide, 1-[5-cyano-4-[[2-(trifluoromethyl)phenyl]methoxy]-2-thienyl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 862813-12-5 CAPLUS  
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.




RN 862813-14-7 CAPLUS  
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-(2-phenylethoxy)- (CA INDEX NAME)




RN 862813-18-1 CAPLUS  
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[2-(2-oxo-1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 862813-19-2 CAPLUS  
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(tetrahydro-2-furanyl)methoxy]- (CA INDEX NAME)



RN 862813-20-5 CAPLUS  
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(tetrahydro-2H-pyran-2-yl)methoxy]- (CA INDEX NAME)




RN 862813-21-6 CAPLUS  
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-(2-phenoxyethoxy)- (CA INDEX NAME)




RN 862813-22-7 CAPLUS  
CN 2-Thiophenecarbonitrile, 3-((1S)-1-(2-chlorophenyl)butoxy)-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862813-23-8 CAPLUS  
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-(3-thienylmethoxy)- (CA INDEX NAME)




RN 862813-24-9 CAPLUS  
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-(2-thienylmethoxy)- (CA INDEX NAME)




RN 862813-25-0 CAPLUS  
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-((1R)-1-methylpropoxy)- (CA INDEX NAME)

Absolute stereochemistry.




IT 660869-28-7 660869-35-0 660869-51-7  
660869-17-0 660869-34-1 660869-42-1  
660869-46-5 660869-47-6 660869-45-7  
660869-40-8 660869-55-6 660869-26-1  
662813-20-3 662813-23-4 662813-20-7  
662813-31-5 662813-32-9 662813-33-0  
662813-34-1 662813-35-2 662813-36-3  
662813-37-4 662813-38-5 662813-39-6  
662813-40-9 662813-41-0 662813-42-1


660869-14-2  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of benzimidazolyl substituted thiophene derivs. with activity against IKK3)  
RN 660869-29-0 CAPLUS  
CN 2-Thiophenecarboxamide, 5-(1H-benzimidazol-1-yl)-3-[(2-methylphenyl)methoxy]- (CA INDEX NAME)




RN 660869-36-0 CAPLUS  
CN 2-Thiophenecarboxamide, 5-(1H-benzimidazol-1-yl)-3-(phenylmethoxy)- (CA INDEX NAME)




RN 660869-91-7 CAPLUS  
CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethyl)phenyl)methoxy]- (CA INDEX NAME)




RN 660869-17-0 CAPLUS  
CN 2-Thiophenecarboxamide, 5-(5-chloro-1H-benzimidazol-1-yl)-3-(phenylmethoxy)- (CA INDEX NAME)



RN 660869-34-1 CAPLUS  
CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(methylsulfonyl)phenyl)methoxy]- (CA INDEX NAME)




RN 660869-42-1 CAPLUS  
CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethoxy)phenyl)methoxy]- (CA INDEX NAME)



RN 660869-46-5 CAPLUS  
CN 2-Thiophenecarboxamide, 3-(cyclohexylmethoxy)-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)


10522958-updated

297 of 356




RN 660869-47-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(tetrahydro-2H-pyran-2-yl)methoxy]]- (CA INDEX NAME)



RN 660869-48-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[2-(4-morpholinyl)ethoxy]]- (CA INDEX NAME)




RN 660869-49-8 CAPLUS

CN 2-Thiophenecarboxamide, 5-[(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-(2-phenylethoxy)]- (CA INDEX NAME)


10522958-updated

298 of 356




RN 660869-55-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(3-bromo-4-pyridinyl)methoxy]-5-[(5,6-dimethoxy-1H-benzimidazol-1-yl)]- (CA INDEX NAME)



RN 862813-26-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[4-(hydroxymethyl)phenyl)methoxy]]- (CA INDEX NAME)




RN 862813-28-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[(5,6-dimethoxy-1H-benzimidazol-1-yl)]- (CA INDEX NAME)

Absolute stereochemistry.


10522958-updated

299 of 356




RN 862813-29-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(1-methyl-1H-benzotriazol-6-yl)methoxy]]- (CA INDEX NAME)



RN 862813-30-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-methoxy-5-[2-(4-morpholinyl)ethoxy]-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl)methoxy]]- (CA INDEX NAME)




RN 862813-31-8 CAPLUS

CN 2-Thiophenecarboxamide, 5-[(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2,5-difluorophenyl)methoxy]]- (CA INDEX NAME)


10522958-updated

300 of 356




RN 862813-32-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(2,6-difluorophenyl)methoxy]-5-[(5,6-dimethoxy-1H-benzimidazol-1-yl)]- (CA INDEX NAME)



RN 862813-33-0 CAPLUS


CN 2-Thiophenecarboxamide, 5-[5-(3-hydroxypropoxy)-6-methoxy-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl)methoxy]]- (CA INDEX NAME)



RN 862813-34-1 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 1-[5-(aminocarbonyl)-4-[[2-(trifluoromethyl)phenyl)methoxy]-2-thienyl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)






RN 862813-35-2 CAPLUS


CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy])- (CA INDEX NAME)

Absolute stereochemistry.




RN 862813-36-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-methoxyphenyl)methoxy])- (CA INDEX NAME)




RN 862813-37-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-oxo-1-pyrrolidinyl)ethoxy])- (CA INDEX NAME)




RN 862813-41-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(3-thienyl)methoxy])- (CA INDEX NAME)



RN 862813-42-1 CAPLUS


CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-thienyl)methoxy])- (CA INDEX NAME)



RN 862813-43-2 CAPLUS


CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(1R)-1-methylpropoxy])- (CA INDEX NAME)

Absolute stereochemistry.




RN 862813-38-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(tetrahydro-2-furanyl)methoxy])- (CA INDEX NAME)



RN 862813-39-6 CAPLUS


CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-phenoxy)ethoxy])- (CA INDEX NAME)



RN 862813-40-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)butoxy]-5-((5,6-dimethoxy-1H-benzimidazol-1-yl))- (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 14 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2005:371254 CAPLUS [Full-text](#)  
DN 142:430276  
TI Process for preparing thienylbenzimidazoles from benzimidazoles and 2-chloro-3-oxo-2,3-dihydrothiophene-2-carboxylates.  
IN Cheung, Mui; Emmitte, Kyle Allen  
PA Smithkline Beecham Corporation, USA  
SO PCT Int. Appl., 85 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005037827	A1	20050428	WO 2004-US33585	20041012
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TW, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, CH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1685128	A1	20060802	EP 2004-794836	20041012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR JP 2007509070 T 20070412 JP 2006-535584 20041012 US 2007060576 A1 20070315 US 2006-575210 20060410 (NOT ODP - PROCESS MAKING)				
PRAI US 2003-511991P	P	20031016	NOT PRIOR ART	
WO 2004-US33585	W	20041012		
OS CASREACT 142:430276; MARPAT 142:430276				
GI				



## FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004000817	A2	20031231	WO 2003-182670	20030612
WO 2004000817	A3	20040521		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MN, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
US 2004002524	A1	20040101	US 2003-460565	20030611
CA 2487266	A1	20031231	CA 2003-2487266	20030612
AU 2003238597	A1	20040106	AU 2003-238597	20030612
BR 7003012069	A	20050329	BR 2003-12069	20030612
EP 1517697	A2	20050330	EP 2003-732945	20030612
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 200554675	T	20051117	JP 2004-515164	20030612
MX 2004PA11123	A	20050214	MX 2004-PA11123	20041109
US 2002 391337P	P	20020624		
WO 2003 182670	W	20030612		
OS MARPAT 140:77149				
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Title compds. I (wherein R1, R2 = independently (un)substituted alkyl, Ph, heteroaryl, cycloalkyl, cycloalkenyl, (un)substituted 4-hydroxyphenyl, R3, R4, R5, R6 = independently H, OH, alkyl, alkoxy, halo; with the proviso that at least one of R1 or R2 must be (un)substituted 4-hydroxyphenyl; their prodrugs, pharmaceutical acceptable salts, or stereoisomeric mixture of I, prodrug or salt) were prepared as estrogen agonists and/or antagonists for treating estrogen receptor-mediated diseases (no data). For example, II was prepared in 5 steps via cyclocondensation of III (preparation given) in AcOH at 80° overnight to the corresponding methoxyphenylbenzimidazole followed by deprotection. Selected I are selective for the ER $\beta$  receptor (no data).

IT 6:15:11-6:4:95, 4-[1-(2-thienyl)-1H-benzimidazol-2-yl]phenol  
 4-[1-(2-thienyl)-1H-benzimidazol-2-yl]phenol  
 R1: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (estrogen agonist/antagonist; preparation of benzimidazoles as estrogen agonists/antagonists)

RN 639523-96-9 CAPLUS  
 CN Phenol, 4-[1-(2-thienyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 639523-98-1 CAPLUS  
 CN Phenol, 4-[1-(2-thienyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)




IT 639523-99-1, 2-(4-Methoxyphenyl)-1-thiophen-3-yl-1H-benzimidazole  
 639523-99-1, 2-(4-Methoxyphenyl)-1-thiophen-2-yl-1H-benzimidazole  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of benzimidazoles as estrogen agonists/antagonists)

RN 639523-97-0 CAPLUS  
 CN 1H-Benzimidazole, 2-(4-methoxyphenyl)-1-(3-thienyl)- (CA INDEX NAME)



RN 639523-99-2 CAPLUS  
 CN 1H-Benzimidazole, 2-(4-methoxyphenyl)-1-(2-thienyl)- (CA INDEX NAME)



X L6 ANSWER 17 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN  
 (NOT 101 B/C NO MOTIVATION TO MODIFY)

AN 2003:199536 CAPLUS Full-text  
 DN 139:52941

T1 N-azolylmethyl ketones as building blocks in heterocyclic synthesis: Synthesis of new polyfunctionally substituted azolylarylazophenols, azolylpyridones and azolylthiophenes

AU Al-Saleh, Balkis; Abdelkhalik, Mervat Mohammed; El-Apasery, Morsy Ahmed; Elmagdi, Mohammed Hilmy

CS Department of Chemistry, Faculty of Science, University of Kuwait, Safat, 13060, Kuwait

SO Journal of Heterocyclic Chemistry (2003), 40(1), 171-175  
 CODEN: JHTCAD; ISSN: 0022-152X

PB HeteroCorporation  
 DT Journal  
 LA English  
 OS CASREACT 139:52841  
 GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. reacted with 2-arylhydrazonopropanals to yield polyfunctionally substituted azolylarylazophenols. e.g. I and II. The reaction of 1-(1H-benzimidazol-1-yl)-2-propanone and 1-(1H-1,2,4-triazol-1-yl)-2-propanone with phenylisothiocyanate in the presence of  $\alpha$ -haloketones afforded the azolylthiophenes III (R = Me, Ph) and IV (R = Me, Ph). The reaction of V with  $\alpha$ -haloketone afforded 5-benzotriazol-1-yl-6-methyl-2-(2-oxopropylsulfonyl)nicotinonitrile VI that was utilized as building blocks for the synthesis of condensed pyridines. Compound VII was condensed with DMF dimethylacetal to yield thieno[2,3-b]pyridin-3-yl-N,N-dimethylformamide derivative VII. This was further cyclized with sodium hydride to 1H-thieno[2,3-b:4,5-b']dipyridin-4-one derivative VIII.

IT 4:44:21 (1) JP 544692 81-1F


RL: SPN (Synthetic preparation); PREP (Preparation)  
 (synthesis of new polyfunctionally substituted azolylarylazophenols, azolylpyridones and azolylthiophenes using N-azolylmethyl ketones as building blocks)

RN 544692-67-3 CAPLUS  
 CN Ethanone, 1-[4-(1H-benzimidazol-1-yl)-3-methyl-5-(phenylamino)-2-thienyl]- (CA INDEX NAME)



RN 544692 81-1 CAPLUS  
 CN Ethanone, 1-[4-(1H-benzimidazol-1-yl)-3-methyl-5-(phenylamino)-2-

thienyl]phenyl- (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN - MAYBE NEXT RE - CHECK!!

AN 2002:849613 CAPLUS Full-text  
 DN 137:353066

T1 Preparation of nitrogenous fused-ring compound having pyrazolyl group as substituents as inhibitors of activation of signal transduction and activation of transcription (STAT6) protein


IN Yoshida, Ichiro; Yoneda, Naoki; Ohashi, Yoshiaki; Suzuki, Shuichi; Miyamoto, Mitsuaki; Miyazaki, Futoshi; Seshimo, Hidenori; Kanata, Junichi; Takase, Yasutaka; Shirato, Manabu; Shimokubo, Daiya; Sakuma, Yoshinori; Yokohama, Hiromitsu

PA Eisai Co., Ltd., Japan  
 SO PCT Int. Appl., 1006 pp.  
 CODEN: PIXXD2

DT Patent  
 LA Japanese


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002089107	A1	20021107	WO 2002-JP4156	20020425
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SE, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 2002253596	A1	20021111	AU 2002-253596	20020425
EP 1382603	A1	20040121	EP 2002-722791	20020425
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 7074901	B1	20060711	US 2003-475585	20031023
PRAI JP 2001-129959	A	20010426		
WO 2002-JP4156	W	20020425		
OS MARPAT 137:353066				
GI				




AB The 4-(N-containing fused aromatic heterocyclyl)pyrazoles (I) or salts thereof, or hydrates of either [X = a nitrogenous fused aromatic heterocyclic group, e.g., imidazo[1,2-a]pyridine, having (R4)n as a substituent; wherein n = an integer of 0-3; R4 = H, halo, cyano, OH, NH2, C1-6 alkyl, halo-C1-6 alkyl, C2-6 alkenyl, C1-6 alkylsulfonyl, C1-6 alkylsulfonylamino, C1-6 alkylsulfinyl, N-mono, or N,N-di(C1-6 alkyl)amino, C1-6 alkoxy, C1-6 alkylsulfinyl, CONH2, etc.; Y = C3-8 cycloalkyl, C4-8 cycloalkenyl, 5- to 14-membered nonarom. or aromatic heterocyclyl, C6-14 aromatic hydrocarbyl, benzene- or 5- or 6-membered aromatic heterocycle-fused 5- to 7-membered nonarom. ring group; Z = H, NH2, halo, HO, NO2, cyano, N3, CHO, HOXN, SO2NH2, guanidino, oxo, C2-6 alkenyl, C1-6 alkoxy, etc.; R1 = H, halo, HO, NO2, cyano, halo-C1-6 alkyl, hydroxy- or cyano-C1-6 alkyl, C2-6 alkenyl, etc.; R2 = H, pyrazolyl, R3 = H, halo, cyano, NH2, C1-4 alkyl, halo-C1-4 alkyl] are prepared. These compds. are inhibitors of STAT6 protein activation and IL-4 and/or IL-13 signal transduction and are useful for prevention and/or treatment of diseases on which the inhibition of STAT6 activation and/or IL-4 and/or IL-13 signal transduction is effective. The diseases include allergy, allergic rhinitis, bronchial asthma, atopic dermatitis, pollinosis, digestive tract allergy, urticaria, hypersensitivity pneumonia, lung aspergillosis, eosinophil leukemia, parasite infection, eosinophilia, eosinophil pneumonia, eosinophil gastroenteritis, autoimmune disease, systemic lupus erythematosus, virus infection, bacteria infection, obesity, overeating (hyperphagia), malignant tumor, and acquired immunodeficiency syndrome (AIDS). Thus, 4-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzimidazole] was coupled with 6-[3-(4-fluorophenyl)-1-trityl-1H-pyrazolyl]-3-iodoimidazo[1,2-a]pyridine in the presence of tetrakis(triphenylphosphine)palladium and K3PO4 in DMF at 75° for 3 h followed by treating a solution of the coupling product in THF and MeOH with 5 N aqueous HCl to give 4-[(6-[3-(4-fluorophenyl)-1H-4-pyrazolyl]imidazo[1,2-a]pyridin-3-yl)benzimidazole] dihydrochloride (II). II showed IC50 of <10 nM for inhibiting the IL-4-induced induction of alkali phosphatase in human embryonic kidney cell transfected with STAT gene and STAT reporter gene.

IT 474695-81-38  
 RL: PAC (Pharmacological activity), SPN (Synthetic preparation), THU (Therapeutic use), BIOL (Biological study), PREP (Preparation), USES (Uses)  
 (preparation of (N-containing heterocyclyl)pyrazole as inhibitors of activation of STAT6 protein and/or IL-4 and/or IL-13 signal transduction as preventives and/or remedies of diseases)  
 RN 474695-81-3 CAPLUS  
 CN 1H-Benzimidazole, 6-bromo-1-[5-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-[5-(methylsulfonyl)-2-thienyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

IT 474711-86-9  
 RL: RCT (Reactant), RACT (Reactant or reagent)  
 (preparation of (N-containing heterocyclyl)pyrazole as inhibitors of activation of STAT6 protein and/or IL-4 and/or IL-13 signal transduction as preventives and/or remedies of diseases)  
 RN 474711-86-9 CAPLUS  
 CN 1H-Benzimidazole, 6-bromo-1-[5-(methylsulfonyl)-2-thienyl]- (CA INDEX NAME)



RN 474711-86-9 CAPLUS  
 CN 1H-Benzimidazole, 5-bromo-1-[5-(methylsulfonyl)-2-thienyl]- (CA INDEX NAME)


RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 19 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2002:716272 CAPLUS [Full-text](#)  
 DN 137:232656  
 TI Preparation of 5-(phenylheteroaryl)-1,3-dihydro-2-benzimidazolone MAP

kinase inhibitors as anti-inflammatory agents  
 IN Dombroski, Mark Anthony; Letavic, Michael Anthony; McClure, Kim Francis  
 PA Prizer Products Inc., USA  
 SO PCT Int. Appl., 272 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1  

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002072576	A1	20020919	WO 2002-IB334	20020130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, ME, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2440211	A1	20020919	CA 2002-2440211	20020130
AU 2002226639	A1	20020924	AU 2002-226639	20020130
EP 1370587	A1	20031217	EP 2002-716257	20020130
EP 1370587	B1	20051116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002007957	A	20040225	BR 2002-7957	20020130
JP 2004526727	T	20040902	JP 2002-571492	20020130
AT 309997	T	20051215	AT 2002-716257	20020130
ES 2251582	T3	20060501	ES 2002-2716257	20020130
US 2003092749	A1	20030515	US 2002-94717	20020311
US 7056918	B2	20060606		
MX 2003PA08142	A	20031212	MX 2003-PA8142	20030909
PRAI US 2001-274791P	P	20010309		
WO 2002-IB334	W	20020130		
OS CASREACT 137:232656, MARPAT 137:232656				
GI				

alkyl(amino)sulfonyl, alkylsulfonyl, carbamoyl, acyl, carboxy, etc.; n = 0-5) were prepared as potent inhibitors of MAP kinases, preferably p38 kinase. For example, (3R)-(-)-1-benzyl-3-aminopyrrolidine was condensed with 1,3-diethyl-2-oxo-2,3-dihydro-1H-benzimidazole-5-carbaldehyde in the presence of MgSO4 in CH2Cl2. Addition of ((4-methylphenylsulfonyl)(m-tolyl)methyl)isocyanide to the 5-(benzylpyrrolidinyl)benzimidazolone using DMF and MP-carbonate gave the 5-(m-tolyl)imidazolyl derivative. Treatment with Pd/C and HCl in MeOH afforded (R)-II-HCl. All of the compds. of the invention that were tested had an IC50 < 10 μM in TNFα and MAPKAP in vitro assays and an ED50 < mg/kg in an in vivo TNFα assay. I are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion of ischemia in stroke or heart attack, autoimmune diseases, and other disorders (no data).  
 IT 459194-73-6P, 3-Methyl-1-thiophen-3-yl-5-(5-(m-tolyl)-3H-imidazol-4-yl)-1,3-dihydrobenzimidazol-2-one  
 RL: PAC (Pharmacological activity), SPN (Synthetic preparation), THU (Therapeutic use), BIOL (Biological study), PREP (Preparation), USES (Uses)  
 (anti-inflammatory agent; preparation of (phenylheteroaryl)benzimidazolone MAP kinase inhibitors as anti-inflammatory agents)  
 RN 459194-73-6 CAPLUS  
 CN 2H-Benzimidazol-2-one, 1,3-dihydro-3-methyl-5-[5-(3-methylphenyl)-1H-imidazol-4-yl]-1-(3-thienyl)- (9CI) (CA INDEX NAME)




X

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN - MAYBE 103 NEXT NE - CHECK!


AN 2001:526062 CAPLUS [Full-text](#)  
 DN 135:107328  
 TI Preparation of 1,2-diarylbenzimidazolealkanoates and analogs for treatment of disorders mediated by microglia activation  
 IN Kuhnke, Joachim; Halfbrodt, Wolfgang; Moening, Ursula  
 PA Schering Aktiengesellschaft, Germany  
 SO PCT Int. Appl., 141 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 FAN.CNT 1  

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001051473	A1	20010719	WO 2001-EP334	20010112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,				




AB Title compds. I [wherein Het = (un)substituted pyrrolol, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl; R1 and R2 = independently H or (un)substituted (cyclo)alkyl, Ph, heteroaryl, or heterocyclyl; R3 = independently halo, (perhalo)alkyl, (perhalo)cycloalkyl, alkenyl, alkynyl, heterocyclyloxy, Ph, OH, (perhalo)alkoxy, OPh, alkylthio,


		LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
	RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BB, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TO					
	CA	2396227	A1	20010719	CA	2001-2396227	20010112
	BR	200107628	A	20021008	BR	2001-7628	20010112
	EP	126808	A	20021009	EP	2001-91513	20010112
		R1, AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	HU	2002004011	A2	20030528	HU	2002-4011	20010112
	JP	2003253291	T	20030812	JP	2001-551855	20010112
	EE	200200390	A	20031015	EE	2002-390	20010112
	WZ	51926	A	20050225	WZ	2001-51926	20010112
	AU	782993	B2	20050915	AU	2001-42332	20010112
	US	2002006948	A1	20020117	US	2001-759360	20010116
	US	711564	B2	20061003			
	IN	2002MN0672	A	20050304	IN	2002-MN672	20020524
	MX	2002PA05742	A	20020918	MX	2002-PA5742	20020610
	BG	106821	A	20030131	BG	2002-106821	20020613
	NO	2002003362	A	20020913	NO	2002-3362	20020712
	UA	2002006470	A	20040219	UA	2002-6470	20020813
	US	2006094770	A1	20060504	US	2005-299135	20051208
	US	2006205803	A1	20060914	US	2005-305521	20051216
	PRAI	DE 2000-10002898	A	20000114			
		WZ 2001-178324P	P	200002127			
		WO 2001-EP934	W	20010112			
		US PAT. 759360	A3	20010116			
OS	GI	MARPAT 1351:10732E					




AE	Title compds. 1: R = Z21R4; R1, R2 = (un)substituted (hetero)aryl; R3 = H, halo, substituted alkyl, alkoxy, etc.; R4 = CO2H, alkoxy carbonyl, CONH2, SO3H, etc.; Z = O, (alkyl)imino, acylimino; Z1 = (heteroatom-interrupted) alkyl(en)ylene, etc. were prepared Thus, I (R1 = R2 = Ph, R3 = H) (I); R = 6-OH) was etherified by BrCH2CO2CHMe3 to give II (R = 6-OCH2CO2CHMe3). Data for biol. activity of I were given.
IT	150232-60-CP 150232-62-AP RL: BAC (Biological activity or effector, etc. opposite adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) [preparation of 1,2-diarylbenzimidazolalkanoates and analogs for treatment of disorders mediated by microglia activation]
RN	150233-60-2 CAPLUS
CN	Hexanoic acid, 6-[[2-phenyl-1-(3-thienyl)-1H-benzimidazol-5-yl]oxy]-, methyl ester, (CA INDEX NAME)




AB	<p> Benzimidazoleoxes [X = CH, N; R1 = (un)substituted Ph, thienyl, thiazolyl; R2, R3 = H, alkyl, aryl, cycloalkyl, OH, NO2, NH2, halo; R4 = (un)substituted Ph, pyridinyl, pyrimidinyl, etc.; R5 = H, alkyl, alkoxy, aryloxy, halo, NH2, NO2, etc.] were prepared as tyrosine kinase inhibitors. Thus, I1 was prepared in 6 steps starting from 4-bromo-1-fluoro-2-nitrobenzene and proceeding via 4'-methoxy-2-nitro-N-phenyl-4-biphenylamine. The products were inhibitors of vascular endothelial growth factor (VEGF) and inhibited VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC50 values of 150-650 nM. </p>
IT	<p> 261634-70-2P 260258-26-2P 260258-27-3P  260258-27-3P 260258-29-5P 260258-30-8P  260258-32-0P 260258-32-1P 260258-42-2P  260258-44-3P 260258-44-4P 260258-45-5P  260258-46-6P 260258-48-3P 260258-49-2P  260258-50-7P 260258-60-4P 260258-61-5P  260258-62-6P 260258-63-7P 260258-64-8P  260258-66-0P 260258-67-3P 260258-77-3P  260258-78-4P 260258-79-5P 260258-82-0P  260258-84-2P 260258-85-6P 260258-88-1P  260258-89-6P 260258-91-2P 260258-93-4P  260258-94-5P 260258-95-6P  260258-96-7P 260258-97-8P  260258-98-9P 260258-99-0P  260258-100-1P 260258-101-2P 260258-102-3P  260258-103-4P 260258-104-5P 260258-105-6P  260258-106-7P 260258-107-8P 260258-108-9P  260258-109-0P 260258-110-1P 260258-111-2P  260258-112-3P 260258-113-4P 260258-114-5P  260258-115-6P 260258-116-7P 260258-117-8P  260258-118-9P 260258-119-0P 260258-120-1P  260258-121-2P 260258-122-3P 260258-123-4P  260258-124-5P 260258-125-6P 260258-126-7P  260258-127-8P 260258-128-9P 260258-129-0P  260258-130-1P 260258-131-2P 260258-132-3P  260258-133-4P 260258-134-5P 260258-135-6P  260258-136-7P 260258-137-8P 260258-138-9P  260258-139-0P 260258-140-1P 260258-141-2P  260258-142-3P 260258-143-4P 260258-144-5P  260258-145-6P 260258-146-7P 260258-147-8P  260258-148-9P 260258-149-0P 260258-150-1P  260258-151-2P 260258-152-3P 260258-153-4P  260258-154-5P 260258-155-6P 260258-156-7P  260258-157-8P 260258-158-9P 260258-159-0P  260258-160-1P 260258-161-2P 260258-162-3P  260258-163-4P 260258-164-5P 260258-165-6P  260258-166-7P 260258-167-8P 260258-168-9P  260258-169-0P 260258-170-1P 260258-171-2P  260258-172-3P 260258-173-4P 260258-174-5P  260258-175-6P 260258-176-7P 260258-177-8P  260258-178-9P 260258-179-0P 260258-180-1P  260258-181-2P 260258-182-3P 260258-183-4P  260258-184-5P 260258-185-6P 260258-186-7P  260258-187-8P 260258-188-9P 260258-189-0P  260258-190-1P 260258-191-2P 260258-192-3P  260258-193-4P 260258-194-5P 260258-195-6P  260258-196-7P 260258-197-8P 260258-198-9P  260258-199-0P 260258-200-1P 260258-201-2P  260258-202-3P 260258-203-4P 260258-204-5P  260258-205-6P 260258-206-7P 260258-207-8P  260258-208-9P 260258-209-0P 260258-210-1P  260258-211-2P 260258-212-3P 260258-213-4P  260258-214-5P 260258-215-6P 260258-216-7P  260258-217-8P 260258-218-9P 260258-219-0P  260258-220-1P 260258-221-2P 260258-222-3P  260258-223-4P 260258-224-5P 260258-225-6P  260258-226-7P 260258-227-8P 260258-228-9P  260258-229-0P 260258-230-1P 260258-231-2P  260258-232-3P 260258-233-4P 260258-234-5P  260258-235-6P 260258-236-7P 260258-237-8P  260258-238-9P 260258-239-0P 260258-240-1P  260258-241-2P 260258-242-3P 260258-243-4P  260258-244-5P 260258-245-6P 260258-246-7P  260258-247-8P 260258-248-9P 260258-249-0P  260258-250-1P 260258-251-2P 260258-252-3P  260258-253-4P 260258-254-5P 260258-255-6P  260258-256-7P 260258-257-8P 260258-258-9P  260258-259-0P 260258-260-1P 260258-261-2P  260258-262-3P 260258-263-4P 260258-264-5P  260258-265-6P 260258-266-7P 260258-267-8P  260258-268-9P 260258-269-0P 260258-270-1P  260258-271-2P 260258-272-3P 260258-273-4P  260258-274-5P 260258-275-6P 260258-276-7P  260258-277-8P 260258-278-9P 260258-279-0P  260258-280-1P 260258-281-2P 260258-282-3P  260258-283-4P 260258-284-5P 260258-285-6P  260258-286-7P 260258-287-8P 260258-288-9P  260258-289-0P 260258-290-1P 260258-291-2P  260258-292-3P 260258-293-4P 260258-294-5P  260258-295-6P 260258-296-7P 260258-297-8P  260258-298-9P 260258-299-0P 260258-300-1P  260258-301-2P 260258-302-3P 260258-303-4P  260258-304-5P 260258-305-6P 260258-306-7P  260258-307-8P 260258-308-9P 260258-309-0P  260258-310-1P 260258-311-2P 260258-312-3P  260258-313-4P 260258-314-5P 260258-315-6P  260258-316-7P 260258-317-8P 260258-318-9P  260258-319-0P 260258-320-1P 260258-321-2P  260258-322-3P 260258-323-4P 260258-32</p>



RN 260254-26-2 CAPLUS  
CN 2(1H)-Pyridinone, 1-[3-(1-piperidinyl)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 350233-62-4 CAPLUS  
CN Hexanoic acid, 6-[(2-phenyl-1-(3-thienyl)-1H-benzimidazol-6-yl)oxy]-,  
methyl ester (CA INDEX NAME)




RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


6	ANSWER 21 OF 36	CAPLUS	COPYRIGHT 2008 ACS on STN		MAYBE 103 NEXT NE
1	CHECK				
AN	1000:891563 CAPLUS <u>Pull Text</u>				
DN	134:42130				
TI	Benzimidazole derivatives as tyrosine kinase inhibitors				
IN	Bilodeau, Mark T.; Cunningham, April M.; Hungate, Randall W.; Koester, Timothy J.				
PA	Merck & Co., Inc., USA				
SO	U.S., 21 pp., Cont.-in-part of U.S. Ser. No. 143,881, abandoned.				
	CODEN: USXXAM				
DT	Patent				
LA	English				
FAN.CNT 4					
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PR	US 6162804	A	20001219	US 1999-266331	19990311
PRAI	US 1997-60151P	P	19970926		
	US 1998-143881	B2	19980831		
OS	MARPAT 134:42130				
GI					




RN 260258-27-3 CAPLUS  
CN 2(1H)-Pyridinone, 1-[2-(1-piperidinyl)ethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-28-4 CAPLUS  
CN 2(1H)-Pyridinone, 1-[2-(4-morpholinyl)ethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-29-5 CAPLUS  
CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-30-8 CAPLUS  
CN 2(1H)-Pyridinone, 1-[(1-methyl-3-piperidiny)methyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-32-0 CAPLUS  
CN 2(1H)-Pyridinone, 1-[2-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-




RN 260258-33-1 CAPLUS  
CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)-2-methylpropyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 260258-42-2 CAPLUS  
CN 2(1H)-Pyridinone, 1-[3-(1-piperidinyl)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-43-3 CAPLUS  
CN 2(1H)-Pyridinone, 1-[2-(1-piperidinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-44-4 CAPLUS  
CN 2(1H)-Pyridinone, 1-[2-(4-morpholinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)


RN 260250-50-2 CAPLUS  
CN 4-Piperidinecarbonitrile, 1-[2-(2-oxo-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]-1(2H)-pyridinyl]ethyl)- (CA INDEX NAME)




PN 260258-60-4 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[3-(1-piperidinyl)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-61-5 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[2-(1-piperidinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-62-6 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[2-(4-morpholinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-63-7 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-45-5 CAPLUS  
CN 2-(1H)-Pyridinone, 1-[3-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)





RN 260258-46-6 CAPLUS  
CN 2(1H)-Pyridinone, 1-[(1-methyl-3-piperidinyl)methyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-48-8 CAPLUS  
CN 2(1H)-Pyridinone, 1-[2-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-49-9 CAPLUS  
CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)-2-methylpropyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-64-8 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[(1-methyl-3-piperidinyl)methyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-66-0 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[2-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-67-1 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)-2-methylpropyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-77-3 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[3-(1-piperidinyl)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-78-4 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[2-((1-piperidinyl)ethyl)-4-((3-thienyl)-1H-benzimidazol-5-yl)]- (CA INDEX NAME)




RN 260258-79-5 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[2-(4-morpholinyl)ethyl)-4-((3-thienyl)-1H-benzimidazol-5-yl)]- (CA INDEX NAME)




RN 260258-82-0 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)propyl)-4-((3-thienyl)-1H-benzimidazol-5-yl)]- (CA INDEX NAME)




RN 260258-84-2 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[[1-methyl-3-piperidinyl)methyl)-4-((3-thienyl)-1H-benzimidazol-5-yl)]- (CA INDEX NAME)




RN 260258-88-6 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[2-(dimethylamino)propyl)-4-((3-thienyl)-1H-benzimidazol-5-yl)]- (CA INDEX NAME)




RN 260258-89-7 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)-2-methylpropyl)-4-((3-thienyl)-1H-benzimidazol-5-yl)]- (CA INDEX NAME)




RN 312959-29-8 CAPLUS  
CN 2(1H)-Pyrimidinone, 4-((3-thienyl)-1H-benzimidazol-5-yl)]- (CA INDEX NAME)




RN 312959-31-2 CAPLUS  
CN 2(1H)-Pyrimidinone, 5-((3-thienyl)-1H-benzimidazol-5-yl)]- (CA INDEX NAME)




RN 312959-33-4 CAPLUS  
CN 2(1H)-Pyrimidinone, 4-((3-thienyl)-1H-benzimidazol-5-yl)]- (CA INDEX NAME)



RN 312959-34-5 CAPLUS  
CN 2(1H)-Pyrimidinone, 4-((3-thienyl)-1H-benzimidazol-5-yl)]- (CA INDEX NAME)



RN 312959-35-6 CAPLUS  
CN 1H-Benzimidazole, 1-(3-thienyl)- (CA INDEX NAME)



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 22 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN - MAYBE NEXT NE - CHECK!

AN 2000:215999 CAPLUS Full-text

DN 132:258111

TI Benzimidazoles, their preparation, hole-transporting materials, electroluminescent devices, and electrophotographic photoreceptors thereof

IN Ueda, Hideaki; Fujino, Yasumitsu; Furukawa, Keiichi

PA Minolta Camera Co., Ltd., Japan


SO Jpn. Kokai Tokkyo Koho, 25 pp.

CODEN: JKKXAP

DT Patent  
LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FI	JP 2000095766	A	20000404	JP 1998-269595	19980924
PRAT	JP 1998-269595		19980924		
OS	MARPAT 132:258111				
GI					




AB The benzimidazole compds. are shown as I (A = arylene, heterocyclic ring which may be linked; Ar1, Ar2 = aryl, heterocyclic ring; R1, R2 = H, alkyl, alkoxy, halo) and are prepared by reacting benzimidazoles II (A, R1, R2 = same as above) with halogens Ar1X and Ar2X (Ar1, Ar2 = same as above; X = halo). The hole-transporting materials for the electrophotog. photoreceptors comprise I and show excellent durability. The electroluminescent devices have 21 layer containing I.

IT 252424-77-5

RL: TEM (Technical or engineered material use); USES (Uses)  
(preparation of benzimidazole deriva. for hole-transporting materials and electroluminescent devices and electrophotog. photoreceptors thereof)

RN 262434-77-5 CAPLUS

CN 2-Thiophenamine, 5,5'-[oxybis(4,1-phenylene-1H-benzimidazole-2,1-diy)]bis[N,N-diphenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 23 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN - MAYBE 103 NEXT NE - CHECK!

AN 2000:161133 CAPLUS Full-text

DN 132:194377

TI Preparation of benzimidazoles and imidazo[4,5-b]pyridines as novel angiogenesis inhibitors

IN Blodreau, Mark T.; Hungate, Randall W.; Cunningham, April M.; Koester, Timothy J.



PA Merck & Co., Inc., USA

SO PCT Int. Appl., 73 pp.

CODEN: PIXX2D

DT Patent  
LA English  
FAN.CNT 4


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000012089	A1	20000309	WO 1999-US5297	19990311
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MM, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2341409	A1	20000309	CA 1999-2341409	19990311
AU 9930789	A1	20000321	AU 1999-30789	19990311
AU 760020	B2	20030508		
EP 1109555	A1	20010627	EP 1999-912408	19990311
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002523459	T	20020730	JP 2000-567206	19990311
US 6465484	B1	20021015	US 2001-786004	20010228
US 1998-143881	A	19980831		
US 1997-60151P	P	19970926		
WO 1999-US5297	W	19990311		
OS MARPAT 132:194377				
GI				




AB The title compds. [I; X = N, CH; R1, R3 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl, aryl, etc.; R4, R5 = H, alkyl, cycloalkyl, etc.] which inhibit tyrosine kinase enzymes, and therefore useful in treating tyrosine kinase-dependent diseases/conditions such as angiogenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals, were prepared. E.g., a multi-step synthesis of the benzimidazole II was given. Compds. I inhibit VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC50 of 150-650 nM.

IT 221636-10-2P 221636-34-6P 260258-26-2P  
260258-27-2P 260258-28-4P 260258-29-5P  
260258-30-8P 260258-31-9P 260258-32-0P


260258-33-1P 260258-34-2P 260258-42-2P  
260258-43-3P 260258-44-4P 260258-45-5P  
260258-46-6P 260258-47-7P 260258-48-6P  
260258-49-9P 260258-50-2P 260258-60-4P  
260258-61-5P 260258-62-6P 260258-63-7P  
260258-64-3P 260258-65-9P 260258-66-0P  
260258-67-1P 260258-68-2P 260258-77-3P  
260258-78-4P 260258-79-5P 260258-82-6P  
260258-84-2P 260258-86-4P 260258-88-6P  
260258-89-7P 260258-90-0P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of benzimidazoles and imidazo[4,5-b]pyridines as novel angiogenesis inhibitors)  
RN 221636-30-2 CAPLUS  
CN 1H-Benzimidazole, 5-[4-[3-(1-piperidinyl)propyl]phenyl]-1-(3-thienyl)- (CA INDEX NAME)




RN 221636-34-6 CAPLUS  
CN 1H-Benzimidazole, 5-[6-[2-(1-piperidinyl)ethoxy]-3-pyridinyl]-1-(3-thienyl)- (CA INDEX NAME)




RN 260258-26-2 CAPLUS  
CN 2(1H)-Pyridinone, 1-[3-(1-piperidinyl)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-27-3 CAPLUS  
CN 2(1H)-Pyridinone, 1-[2-(1-piperidinyl)ethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-28-4 CAPLUS  
CN 2(1H)-Pyridinone, 1-[2-(4-morpholinyl)ethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-29-5 CAPLUS  
CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 260258-30-8 CAPLUS  
CN 2(1H)-Pyridinone, 1-[1-(1-methyl-3-piperidinyl)methyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-31-9 CAPLUS  
CN 2(1H)-Pyridinone, 1-[3-(4-methyl-1-piperazinyl)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-32-0 CAPLUS  
CN 2(1H)-Pyridinone, 1-[2-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)


benzimidazol-5-yl)- (CA INDEX NAME)




RN 260258-33-1 CAPLUS  
CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)-2-methylpropyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 260258-34-2 CAPLUS  
CN 4-Piperidinecarbonitrile, 1-[2-[2-oxo-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]-1(2H)-pyridinyl]ethyl]- (CA INDEX NAME)




RN 260258-42-2 CAPLUS  
CN 2(1H)-Pyridinone, 1-[3-(1-piperidinyl)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-43-3 CAPLUS  
CN 2(1H)-Pyridinone, 1-[2-(1-piperidinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)







RN 260258-44-4 CAPLUS  
CN 2(1H)-Pyridinone, 1-[2-(4-morpholinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)





RN 260258 45-5 CAPLUS  
CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-46-6 CAPLUS  
CN 2(1H)-Pyridinone, 1-[(1-methyl-3-piperidinyl)methyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-47-7 CAPLUS  
CN 2(1H)-Pyridinone, 1-[3-(4-methyl-1-piperazinyl)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-62-6 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[2-(4-morpholinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 260258-63-7 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-64-8 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[(1-methyl-3-piperidiny)methyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-t5-9 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[3-(4-methyl-1-piperazinyl)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)


RN 260258-48-8 CAPLUS  
CN 2(1H)-Pyridinone, 1-[2-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-49-9 CAPLUS  
CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)-2-methylpropyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-50-2 CAPLUS  
CN 4-Piperidinecarbonitrile, 1-[2-[2-oxo-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]-1(2H)-pyridinyl]ethyl]- (CA INDEX NAME)




RN 260258-60-4 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[3-(1-piperidinyl)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-61-5 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[2-(1-piperidinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN . 260258-66-0 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[2-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-67-1 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)-2-methylpropyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-68-2 CAPLUS  
CN 4-Piperidinecarbonitrile, 1-[2-[2-oxo-5-(1-(3-thienyl)-1H-benzimidazol-5-yl)-1(2H)-pyrimidinyl]ethyl]- (CA INDEX NAME)




RN 260258-77-3 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[3-(1-piperidinyl)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-78-4 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[2-(1-piperidinyl)ethyl]-4-(1-(3-thienyl)-1H-benzimidazol-5-yl)- (CA INDEX NAME)




RN 260258-79-5 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[2-(4-morpholinyl)ethyl]-4-[1-(3-chienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 260258-82-0 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-84-2 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[(1-methyl-3-piperidinyl)methyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RE.CNT 12      THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 24 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN - DEFINITELY APPEARS TO BE  
103 NEXT NX


AN	1999;748015	CAPLUS	<u>Full-text</u>		
DN	131;351330				
TI	Preparation of 1-phenylbenzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation				
IN	Boschelli, Diane Harris; Denny, William Alexander; Doherty, Annette Martin; Hamby, James Marino; Khatana, Sonya Shah; Kramer, James Bernard; Palmer, Brian Desmond; Showalter, Howard Daniel Hollis				
PA	Warner-Lambert Company, USA				
SO	U.S., 25 pp.				
DO	CODEN: USXXAM				
DT	Patent				
LA	English				
FAM_CNT	1				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----			-----	
PI	US 5990146	A	19991123	US 1998-135470	19980817
	US 6218388	B1	200104127	US 1999-459011	19991210
PRAI	US 1997-56609P	P	19970820		
	US 1998-135470	A3	19980817		
	US 1999-408630	A3	19990930		
QS	MARPAT 131;351330				
GI					




AB	The title compds. [1; Ar = (un)substituted aryl, R1-R4 = H, alkyl, halo, etc.] and their pharmacologically acceptable salts, inhibitors of protein tyrosine kinases such as PDGF and PDGFR, which are useful in treating cellular hyperproliferation disorders such as psoriasis, melanoma, melanocytic nevi, and psoriasis, were prepared. Thus, reduction of 1-(4-nitrophenyl)benzimidazole over Raney Ni in THF afforded 79% 1.2HCl [4; 4-H2NCH6H4; R1-R4 = H] which showed IC50 of > 10 nM against PDGF-stimulated receptor autophosphorylation in rat aorta smooth muscle cells.
IT	796601-15 JP 200671-4-49 Rt; BAC (Biological activity or effector, except adenosine); BSU (Biological




RN 260258-86-4 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[3-(4-methyl-1-piperazinyl)propyl]-4-(1-(3-thienyl)-1H-benzimidazol-5-yl)- (CA INDEX NAME)



RN 260258-88-6 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[2-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-89-7 CAPLUS  
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)-2-methylpropyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 260250-90-0 CAPLUS  
CN 4-Piperidinecarbonitrile, 1-[2-[2-oxo-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]-1(2H)-pyrimidinyl]ethyl]- (CA INDEX NAME)


study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 1-phenylbenzimidazoles for inhibiting protein tyrosine  
kinase mediated cellular proliferation)

RN 250691-87-3 CAPLUS  
CN 1H-Benzimidazole, 5-methoxy-1-(2-thienyl)-, monohydrochloride (9CI) (CA  
INDEX NAME)



● HCl

RN 250691-88-4 CAPLUS  
CN 1H-Benzimidazole, 5-methoxy-1-(3-thienyl)-, monohydrochloride (9CI) (CA  
INDEX NAME)



● HCl


RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

1.6 ANSWER 25 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN - DEFINITELY CHECK

IN 1999;233907 CAPLUS ~~Pull-core~~ ~~CONFIDENTIAL~~ 2006 ACS on SIN - DEFINITIVE CHECK  
 DN 130:252359  
 TI Preparation of benzimidazoles and imidazopyridines as tyrosine kinase  
 inhibitors  
 IN Bilocheau, Mark T.; Hungate, Randall W.; Cunningham, April M.; Koester,  
 PA Marck & Co., Inc., USA  
 SO PCT Int. Appl., 40 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 EAN-CNT 4

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	NO 9916755	A1	19990408	NO 1998-US19789	19980922
N: AL, AM, AU, A2, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HK, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LG, LR, LT, LV, MD, MG, MR, MN, MX, NO, NZ, PL, PT, RU, RJ, SI, SK, SL, TJ, TR, TT, UA, US, UZ, VN, YU, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ					
RM: CH, CM, CN, DE, DK, EE, ES, FI, FR, GB, GR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LG, LR, LT, LV, MD, MG, MR, MN, MX, NO, NZ, PL, PT, RU, RJ, SI, SK, SL, TJ, TR, TT, UA, US, UZ, VN, YU, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ					


CM, GA, GN, GW, MU, MR, NE, SN, TD, TG  
 CA 2302830 A1 19990408 CA 1998-2303830 19980922  
 AU 9855003 A 19990423 AU 1998-95003 19980922  
 AU 744939 B2 20020307  
 EP 1017662 A1 20000712 EP 1998-948427 19980922  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,  
 SI, LT, LV, FI, RO  
 JP 2001518470 T 20011016 JP 2000-513841 19980922  
 PRAI: US 1997-60151P P 19970926  
 GB 1998-10544 A 19980515  
 WO 1998-US19789 W 19980922  
 OS MARPAT 130:252359  
 GI




AB The title compds. I [X = N, C; R1 = H, alkyl, cycloalkyl, halo, etc.; R2, R3 = H, alkyl, aryl, OH, etc.; R4 = H, alkyl, alkoxy, alkenyl, etc.; R5 = H, alkyl, halo, etc.], which inhibit tyrosine kinase enzymes, were prepared. E.g., 1-phenyl-5-(4-methoxyphenyl)benzimidazole was prepared.

IT 221636-20-2 CAPLUS  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of benzimidazoles and imidazopyridines as tyrosine kinase inhibitors)


RN 221636-20-2 CAPLUS  
 CN 1H-Benzimidazole, 5-[4-{3-(1-piperidinyl)propyl}phenyl]-1-(3-thienyl)- (CA INDEX NAME)



RN 221636-34-6 CAPLUS  
 CN 1H-Benzimidazole, 5-[6-[2-(1-piperidinyl)ethoxy]-3-pyridinyl]-1-(3-thienyl)- (CA INDEX NAME)



RN 220495-92-1 CAPLUS  
 CN 1H-Benzimidazole, 4-methoxy-1-(3-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN - DEFINITELY CHECK FOR 103! THIS WAS MY PRIMARY REFERENCE IN FAOM - MAYBE CAN USE THIS TO 103 INSTEAD

AN 1998:785290 CAPLUS Full-text  
 DN 130:177118  
 TI Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor  
 AU Palmer, Brian D.; Smail, Jeff B.; Boyd, Maruta; Boschelli, Dianne H.; Doherty, Annette M.; Hamby, James M.; Khataha, Sonya S.; Kramer, James B.; Kraker, Alan J.; Panek, Robert L.; Lu, Gina H.; Dahring, Tawny K.; Winters, R. Thomas; Showalter, H. D. Hollis; Denny, William A.  
 CS Auckland Cancer Society Research Centre Faculty of Medicine and Health Sciences, The University of Auckland School of Medicine, Auckland, N. Z.  
 SO Journal of Medicinal Chemistry (1998), 41(27), 5457-5465  
 CODEN: JMCNAR; ISSN: 0022-2623  
 DB American Chemical Society  
 DT Journal  
 LA English  
 AB 1-Phenylbenzimidazoles are shown to be a new class of ATP-site inhibitors of the platelet-derived growth factor receptor (PDGFR). Structure-activity relationships (SARs) are narrow, with closely related heterocycles being inactive. A systematic study of substituted 1-phenylbenzimidazoles showed clear SARs. Substituents at the 4'- and 3'-positions of the Ph ring are tolerated but do not significantly improve activity, while substituents at the 2'-position abolish it. Substituents in the 2-, 4-, and 7-positions of the benzimidazole ring (with the exception of 4-OH) also abolish activity. Most substituents at the 5- and 6-positions maintain or increase activity, with the 5-OH, 5-OMe, 5-COMe, and 5-CO2Me analogs being >10-fold more potent than the parent 1-phenylbenzimidazole. The 5-OMe analog was both the most potent inhibitor, and showed the highest selectivity (50-fold) between PDGFR and PGFR isolated enzymes, and also a moderately effective inhibitor (IC50 = 1.9 μM) of PDGF-stimulated PDGFR autophosphorylation in rat aorta smooth muscle cells.  
 IT 221636-20-2 CAPLUS  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor)  
 RN 220495-91-0 CAPLUS  
 CN 1H-Benzimidazole, 4-methoxy-1-(2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

ONLY CHECKED TO SEE IF ELECTED SPECIES ALLOWABLE OVER REFERENCES 27-36

L6 ANSWER 27 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN  
 AN 1989:85382 CAPLUS Full-text  
 DN 110:85382  
 TI Electrophotographic photoreceptor containing charge-transporting benzimidazole derivative  
 IN Shiino, Yasuko; Matsumoto, Masakazu  
 PA Canon K. K., Japan  
 SO Jpn. Kokai Tokkyo Koho, 13 pp.  
 CODEN: JKKXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1  

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63157157	A	19880630	JP 1986-303856	19861222
PRAI JP 1986-303856		19861222		


 G1



AB The title photoreceptor has a photosensitive layer containing a benzimidazole derivative I (R1 = alkyl, aryl, heterocyclyl; R2, R3 = H, R1, aralkyl; R2, R3, and the central C may form a ring residue; A = aralkyl, R1).


IT 119028-39-6  
 RL: TEM (Technical or engineered material use); USES (Uses)  
 (electrophotograph, charge-transporting agent)

RN 119028-39-6 CAPLUS  
 CN Benzenamine, N,N-dimethyl-4-[[1-(2-thienyl)-5-(9H-xanthen-9-ylidenemethyl)-1H-benzimidazol-2-yl]]- (CA INDEX NAME)




L6 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN  
 AN 1988:562796 CAPLUS Full-text


DN 109:162796  
 TI Determination of telenzepine in human serum by gas chromatography-mass spectrometry  
 AU Sturm, E.; Junker, A.  
 CS Byk Gulden Pharm., Konstanz, D-7750, Fed. Rep. Ger.  
 SO Journal of Chromatography (1988), 430(1), 43-51  
 CODEN: JOCRAM; ISSN: 0021-9673  
 DT Journal  
 LA English  
 OS CASREACT 109:162796  
 AB A method for determining telenzepine in human serum is described. Analytes are obtained from alkalized serum by extraction of the drug using reversed-phase octadecylsilane-bonded silica cartridges. Telenzepine and a demethyl analog added to serum as internal standard are retained on the C18 cartridge and recovered by elution with MeOH. The gas chromatog. properties of telenzepine and the internal standard are improved by a 2-step derivatization involving a benzodiazepinone-benzimidazole rearrangement and simultaneous formation of a Me ester function. The processed extract is analyzed by gas chromatog.-mass spectrometry with selected-ion monitoring. Quantification is linear over the range 2-40 ng/mL. Inter-day precision is within 7%, except at the detection limit of 2 ng/mL (16%). Application of this assay to routine anal. is limited by the extensive sample pretreatment essential for derivatization of telenzepine.  
 IT 117019-16-6F 117019-17-7P 117019-18-AP  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, for telenzepine determination in human blood by gas chromatog.)  
 RN 117019-16-6 CAPLUS  
 CN 3-Thiophenecarboxylic acid, 5-methyl-4-[2-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)



RN 117019-17-7 CAPLUS  
 CN 3-Thiophenecarboxylic acid, 4-[2-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 113387-86-3 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-4-chloro-3-hydroxy-, methyl ester (CA INDEX NAME)



L6 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 1988:131570 CAPLUS Full-text  
 DN 108:131570  
 TI Process for the preparation of 3-hydroxy-5-(1-polyazazolyl)-2-methoxycarbonylthiophenes, useful as pharmaceuticals or their intermediates  
 IN Corral Saleta, Carlos; Lissavetzky Diez, Jaime  
 PA Consejo Superior de Investigaciones Científicas, Spain  
 SO Span., 7 pp.  
 CODEN: SPXXAD  
 DT Patent  
 LA Spanish  
 FAN.CNT 1  


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 547442	A1	19861116	ES 1985-547442	19850930
PRAI ES 1985-547442		19850930		

 GI




AB The title compds. (I; X = H, halo; R = heterocyclic polyazazole or benzopolyazazole), useful as intermediate or final products in the synthesis of new therapeutic agents (no data), are prepared by condensation with chloro(methoxycarbonyl)oxodihydrothiophenes II with 3 equivalent polyazazole or benzopolyazazole RH at room temperature. A solution of 0.009 mol II (X = H) in HOAc was treated with 0.018 mol pyrazole and kept at room temperature for 2 days to give crystalline I (X = H, R = 1-pyrazolyl).  
 IT 113387-85-2P 113387-86-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as drug and/or intermediate)  
 RN 113387-85-2 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-3-hydroxy-, methyl


RN 117019-18-8 CAPLUS  
 CN 3-Thiophenecarboxylic acid, 5-methyl-4-[2-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)




L6 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 1988:150195 CAPLUS Full-text  
 DN 108:150195  
 TI Reactions of methyl 3-hydroxythiophene-2-carboxylate. Part 4. Synthesis of methyl 5-azolyl-3-hydroxythiophene-2-carboxylates  
 AU Corral, Carlos; El-Ashawy, Mahmoud B.; Lissavetzky, Jaime; Manzanares, Ignacio  
 CS Inst. Quim. Med., CSIC, Madrid, 28006, Spain  
 SO Journal of Heterocyclic Chemistry (1987), 24(5), 1301-3  
 CODEN: JHTCAD; ISSN: 0022-152X  
 DT Journal  
 LA English  
 OS CASREACT 108:150195  
 GI




AB Oxodihydrothienones I (R1 = H, Cl) were treated with heterocycles, e.g., pyrazole, imidazole, benzotriazole to give thienones II (R2 = 1-pyrazolyl, 1-imidazolyl, 1-benzotriazolyl, etc.).  
 IT 113387-85-2P 113387-86-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 113387-85-2 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)



ester (CA INDEX NAME)



RN 113387-86-3 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-4-chloro-3-hydroxy-, methyl ester (CA INDEX NAME)



L6 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 1986:198778 CAPLUS Full-text  
 DN 104:198778  
 OREF 104:31269a,31272a  
 TI Synthesis, structure, and interconversion of polypyrazolylborate complexes of molybdenum(V)  
 AU Lincoln, Sandra; Koch, Stephen A.  
 CS Dep. Phys. Life Sci., Univ. Portland, Portland, OR, 97203, USA  
 SO Inorganic Chemistry (1986), 25(10), 1594-602  
 CODEN: INOCAJ; ISSN: 0020-1669  
 DT Journal  
 LA English  
 AB HB(pz)3MoCl2 (I; pz = pyrazolyl) was prepared by the reaction of O2 with HB(pz)3MoCl3. Two HB(pz)3MoCl2O (II) geometric isomers and HB(pz)32Mo2O2(μ-O)2 (III) were obtained from the reaction of MoCl5 and HB(pz)3 in dilute HCl. Mo4(HB(pz)3)2(O)4(μ-O)4(μ-OMe)2(HOMe)2 (IV) was prepared from the reaction of III with MeOH. I, II, and IV were structurally characterized by x-ray diffraction. II have the structures typical of Mo2O34- dimers with linear Mo-O-Mo bridges; they provide the 1st example of Mo:Mo distortional isomers with a d1 electronic configuration: the Mo-oxo distance of 1.670(4) and 1.779(6) Å. The yellow-brown colors of II with intense bands at 21,045 cm-1 indicate that the previous interpretations of the electronic spectra of Mo2O34- complexes must be reevaluated. The chemical and crystallog. characterization of IV indicated that it is a Mo(V) tetramer with a zigzag chain of 4 Mo atoms. The importance of correctly distinguishing between a coordinated alkoxide and a coordinated alc. is demonstrated in the structure of IV and by the reformulation of 2 Mo(V) tetramers that had been previously reported in the literature as mixed-valence complexes.  
 IT 101315-85-9  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reformulation of alkoxo complex as)  
 RN 101315-85-9 CAPLUS


CN Molybdate(2-), tetrachlorobis(ethanol)di-μ-ethoxydi-μ-oxodi-μ-oxotetraoxotetra-, (2Mo-Mo), stereoisomer, dihydrogen, compd. with 1,2-di-2-thienyl-1H-benzimidazole (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 101315-84-8

CMF C# H22 C14 Mo4 O12 . 2 H

CCI CCS




● 2 H<sup>+</sup>

CM 2

CRN 101315-83-7

CMF C15 H10 N2 S2



L6 ANSWER 32 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1984:156539 CAPLUS [Full-text](#)

DN 100:156539

OREF 100:23847a,23850a

TI Compounds with antiulcer and antiseecretory activity. II.

3-Heteroaryl-benzimidazolin-2-ones

AU Bianchi, Mario; Butti, Alina; Rossi, Silvano; Barzaghi, Fernando;

Marcara, Viviana

CS Dep. Chem. Synth., Roussel-Maestretti S.p.A., Milan, Italy


SO European Journal of Medicinal Chemistry (1983), 18(6), 495-500

CODEN: EJMCAS; ISSN: 0609-4374

DT Journal

LA English

GI



AB Thienobenzodiazepines I (R = H, F) were prepared by sequential reaction of Et 2-amino-5-ethylthiophene-3-carboxylate with 2,5-F(R)C6H3NO2 II (R = H, F) in the presence of BuLi, catalytic reduction, and cyclization of the resulting amino esters III by 3 equiv NaCH2SOMe (70°, N). Thienobenzodiazepines IV and V were prepared analogously from reactions of Me 3-aminothiophene-2-carboxylate and Me 4-aminothiophene-3-carboxylate, resp., with II. An attempted cyclization of III (R = F) with 1 equiv NaCH2SOMe at 280° gave the rearranged benzimidazolone product VI.


IT 65092-66-2

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 69363-54-4 CAPLUS

CN 2H-Benzimidazol-2-one, 1-(5-ethyl-2-thienyl)-5-fluoro-1,3-dihydro- (CA INDEX NAME)



L6 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1978:37692 CAPLUS [Full-text](#)

DN 88:37692

OREF 88:5917a,5920a

TI Synthesis of nitroheterocycles: Part IV. Syntheses of 1-substituted

4-nitroisquinolines, 5- and 6-nitroindazoles and 6-nitrobenzimidazoles

AU Arya, V. P.; Fernandes, F.; Honkan, V.; Ray, D. K.; Shrivastava, V. B.

CS Ciba-Geigy Res. Cent., Bombay, India

SO Indian Journal of Chemistry, Section B: Organic Chemistry Including

Medicinal Chemistry (1977), 15B(7), 625-8


CODEN: IJSDDB; ISSN: 0376-4699

DT Journal

LA English

OS CASREACT 88:37692

GI



AB Benzimidazolones I (R = H, Me, Et, CHMe2; R1 = (un)substituted pyridyl, pyrazinyl, 2-pyrimidinyl, pyridazinyl, 2-quinolyl, 3-thienyl, 2-thiazolyl, 5-tetrazolyl, 5-methyl-1,2,4-oxadiazol-3-yl; R2 = H, 5-Cl, 6-Cl, 5-CF3) (24 compds.) were prepared by various methods. I (R = Me, R1 = pyrazinyl, R2 = 5-Cl) had the best antiseecretory and antiulcer activity, but induced convulsions, vomiting, and diarrhea on repeated oral administration in dogs.


IT 65092-66-2

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and antiulcer and antiseecretory activity of)

RN 89660-06-0 CAPLUS

CN 2H-Benzimidazol-2-one, 5-chloro-1,3-dihydro-1-methyl-3-(3-thienyl)- (CA INDEX NAME)



L6 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1979:121555 CAPLUS [Full-text](#)

DN 90:121555

OREF 90:19247a,19250a

TI Heteroarene fused benzodiazepines. Part 1. Synthesis of

thieno[2,3-b][1,5]-, -[3,2-b][1,5]-, and -[3,4-b][1,5]benzodiazepines

AU Chakrabarti, Jiban K.; Hicks, Terence A.; Hotten, Terrence M.; Tupper,

David E.

CS Lilly Res. Cent. Ltd., Windlesham, UK

SO Journal of the Chemical Society, Perkin Transactions 1: Organic and

Bio-Organic Chemistry (1972-1999) (1978), (9), 937-41


CODEN: JCPRB4; ISSN: 0300-922X

DT Journal

LA English

OS CASREACT 90:121555

GI



AB 1-Chloro-4-nitroisquinoline (I) was treated with oxazolidin-2-one and thiazolidin-2-one in the presence of NaH to give II (X = O, S), resp. Reaction of I with H2NCH2CH(OMe)2 gives III which was cyclized to give IV. 5- and 6-nitroindazoles react with 2-halo-3- or 5-substituted-pyridines in the presence of NaH in DMF to yield 1-substituted 5- and 6-nitroindazoles (e.g., V). Similar reaction of 6-nitrobenzimidazole sodium salt with compds. containing reactive chlorine affords 1-substituted-6-nitrobenzimidazoles (e.g., VI). The prepared compds. possess no appreciable in vivo antibacterial, antifungal, antiamoebic or antiparasitic activity.


IT 65092-66-2

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 65092-66-2 CAPLUS

CN Thiophene-3-ol tetrahydro-4-(6-nitro-1H-benzimidazol-1-yl)-, 1,1-dioxide (CA INDEX NAME)



L6 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1975:497232 CAPLUS [Full-text](#)

DN 83:97232

OREF 83:15277a,15280a

TI Synthesis of 4,9-dihydro-9-(2-dimethylaminoethyl)-4-methylthieno[3,4-

b][1,5]benzodiazepin-10-one, a benzodiazepine-analogous chlophenone derivative


AU Hronacko, Otto; Binder, Dieter; Eichinger, Karl

CS Inst. Org. Chem., Tech. Hochschule, Wien, Vienna, Austria


SO Monatshefte fuer Chemie (1975), 106(2), 375-9

CODEN: MOCMB7; ISSN: 0026-9247

DT Journal  
LA German  
GI For diagram(s), see printed CA Issue.  
AB Condensation of o-C<sub>6</sub>H<sub>4</sub>(NH<sub>2</sub>)<sub>2</sub> with thiophene I in boiling xylene gave 5% thienobenzimidazepinone II and 58% thienylbenzimidazolone III and IV. Decreasing the temperature by use of boiling toluene gave 46% II, but lower temps. did not give better yields. II was aromatized to V (R = R<sub>1</sub> = H), which was methylated to V (R = Me, R<sub>1</sub> = H) and then treated with Cl(CH<sub>2</sub>)<sub>2</sub>NMe<sub>2</sub> to give V (R = Me, R<sub>1</sub> = (CH<sub>2</sub>)<sub>2</sub>NMe<sub>2</sub>).  
IT 56276-54-1P  
RN 56276-54-1 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-(2,5-dihydro-3-thienyl)-1,3-dihydro- (CA INDEX NAME)




IT 56276-55-2P  
RN 56276-55-2 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-(4,5-dihydro-3-thienyl)-1,3-dihydro- (CA INDEX NAME)




L6 ANSWER 36 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 1975:497128 CAPLUS [Full-text](#)  
DN 83:97128  
OREF 83:15253a,15256a  
TI Synthesis of 1,3-dihydro-3-(2-dimethylaminoethyl)-1-(3-thienyl)benzimidazol-2-ones  
AU Hromatka, Otto; Binder, Dieter; Eichinger, Karl  
CS Inst. Org. Chem., Tech. Hochschule, Wien, Vienna, Austria  
SO Monatshefte fuer Chemie (1975), 106(2), 555-8  
CODEN: MOCMB7; ISSN: 0026-9247  
DT Journal  
LA German  
OS CASREACT 83:97128  
GI For diagram(s), see printed CA Issue.  
AB Benzimidazolone (I, R = H) (II) was prepared by condensation of o-(H<sub>2</sub>N)2C<sub>6</sub>H<sub>4</sub> with Me tetrahydro-4-oxo-3-thiophenecarboxylate. Amination of II by


Cl(CH<sub>2</sub>)<sub>2</sub>NMe<sub>2</sub> gave I (R = CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>). Dehydrogenation of II by chloranil gave benzimidazolone (III, R = X = H) which was aminated to give III (R = CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, X = H). Addnl. obtained were III (R = H, CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, X = Cl).  
IT 56276-54-1P 56276-55-2P 56477-00-0P 56477-01-1P 56477-02-2P 56477-03-3P 56477-04-4P 56477-05-5P  
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)  
RN 56276-54-1 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-(2,5-dihydro-3-thienyl)-1,3-dihydro- (CA INDEX NAME)




RN 56276-55-2 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-(4,5-dihydro-3-thienyl)-1,3-dihydro- (CA INDEX NAME)




RN 56477-00-0 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-(2,5-dihydro-3-thienyl)-3-(2-(dimethylamino)ethyl)-1,3-dihydro- (CA INDEX NAME)




RN 56477-01-1 CAPLUS  
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-(3-thienyl)- (CA INDEX NAME)




RN 56477-02-2 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-(2-chloro-3-thienyl)-1,3-dihydro- (CA INDEX NAME)



RN 56477-03-3 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[2-(dimethylamino)ethyl]-1,3-dihydro-3-(3-thienyl)- (CA INDEX NAME)




RN 56477-04-4 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-(2-chloro-3-thienyl)-3-[2-(dimethylamino)ethyl]-1,3-dihydro- (CA INDEX NAME)



RN 56477-05-5 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-(2-chloro-3-thienyl)-3-[2-(dimethylamino)ethyl]-1,3-dihydro-, compd. with 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CN 56477-04-4  
CMF C15 H16 Cl N3 O 8



CM 2

CRN 88-89-1  
CMF C6 H3 N3 O7

